Methods for normalization and quantification of sequencing data

Universal internal quantification standards in NGS workflows address variability and quantification challenges, enabling accurate and reliable detection of pathogens by normalizing sequencing data with a fixed normalization factor, improving diagnostic accuracy.

JP7590954B2Active Publication Date: 2024-11-27BIOFIRE DIAGNOSTICS LLC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021506373
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-04-20
Filing Date
2019-04-18
Publication Date
2024-11-27
Estimated Expiration
2039-04-18

AI Technical Summary

Technical Problem

Next-generation sequencing (NGS) technologies face challenges in clinical and diagnostic applications due to high intra- and inter-laboratory variability, difficulty in distinguishing clinically relevant pathogens from commensal organisms, and limitations in quantifying nucleic acids without absolute concentration references, leading to inaccurate and less specific results.

Method used

The implementation of universal internal quantification standards (IQS) in NGS workflows that are not specific to targets or samples, allowing for simultaneous quantification of multiple species and accounting for assay-specific and matrix-derived variance, with methods that include adding a known amount of IQS to samples, sequencing, and normalizing data using a fixed normalization factor to ensure consistent limit of detection across samples.

Benefits of technology

This approach provides accurate, absolute quantification of nucleic acids, reduces variability, and enhances the diagnostic power of NGS by ensuring consistent and reliable detection of pathogens, independent of sample preparation errors or sequencing efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590954000004
    Figure 0007590954000004
  • Figure 0007590954000005
    Figure 0007590954000005
  • Figure 0007590954000006
    Figure 0007590954000006
Patent Text Reader

Abstract

Methods and kits for normalization and quantification of sequencing data. [Selected figure] Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 660,460, filed April 20, 2018, the entirety of which is incorporated herein by reference. [Background technology]

[0002] It is difficult to overstate the impact that the ability to decipher base sequences containing polynucleotides has had on biological research. For the better part of the past 40 years, dideoxy-DNA "Sanger" sequencing has been the standard sequencing technique used in many laboratories, culminating in the completion of the human genome sequence. However, because Sanger sequencing is performed on a single amplicon, the throughput of Sanger sequencing is limited, and large-scale Sanger sequencing projects are expensive and challenging.

[0003] DNA sequencing methodology has been transformed by the advent of "next-generation" sequencing (NGS) technologies, which process hundreds of thousands to millions of DNA fragments in parallel, resulting in gigabases (Gb) to terabases (Tb) scale throughput in a single sequencing run at low cost per base of sequence produced. This is astonishing in light of the fact that the first human genome, triumphantly published by both Science and Nature in 2001, took 15 years to sequence and cost nearly $3 billion. In contrast, modern NGS sequencers can sequence more than 45 human genomes in a day for roughly $1000. As a result, NGS can now be used to define features of entire genomes and delineate the differences between them, enabling researchers to better understand the full range of genetic variation and its role in phenotypic variation and the pathogenesis of complex constitutional disorders.

[0004] Nevertheless, the application of NGS for clinical and diagnostic uses may be limited by high intra- and inter-laboratory variability. These issues hinder the use of these sequencing methods in molecular diagnostics, reducing the value of any results. For example, the complexity and variability of NGS library preparation and sequencing reaction setup can lead to sample-to-sample and inter-laboratory variability, which can make it difficult to determine, for example, the prevalence of pathogens or genetic mutations detected in a sample.

[0005] In another example, many of the pathogens targeted in diagnostic assays (e.g., FilmArray panels, BioFire, SLC, UT) are found in the environment and as commensals at the sample collection site. For example, in diseases such as pneumonia, the most frequently encountered bacterial pathogens may also be present as "resident flora" of the oropharyngeal tract, which is often the site of sample collection (saliva and tracheal aspirates or nasopharyngeal swabs (NPS)) or more invasive specimen collection routes such as bronchoalveolar lavage (BAL). Frequent contamination with or co-recovery of resident flora is essentially unavoidable in such cases. In such situations, the diagnostic power of NGS may be limited by the fact that it cannot easily distinguish clinically relevant organisms from commensals or contaminants (e.g., NGS may detect the presence of a pathogen (i.e., pathogen-derived nucleic acid) and its relative abundance (%) relative to other detected nucleic acids or organisms without providing any indication as to whether the detected pathogen is present at a clinically relevant concentration), due to its potential to detect the presence of both highly and minimally enriched organisms (i.e., NGS has an almost infinite dynamic range) without providing much inherent context for interpreting the clinical relevance of the detection in the sequencing data.

[0006] Traditional practice in microbiology laboratories has been to perform semi-quantitative or quantitative cultures to distinguish bacterial pathogenic loads from carriage of clinically irrelevant commensals. Different diagnostic titer guidelines exist for different types of specimens. A similar approach has been applied to NGS assays. Since NGS inherently provides semi-quantitative data, in the absence of confounding factors such as sample preparation errors or differences in sequencing efficiency, the number of sequencing reads for a target can be related to the abundance of the target. Several groups have taken advantage of this correlation to obtain relative quantification data for unknown nucleic acids in NGS. For example, the relative abundance of a nucleic acid in a sample can be determined by performing a series of serial dilutions (illustratively 10-fold dilutions) of one or more samples, sequencing the series of diluted samples, and then plotting the number of reads seen in each. These groups hypothesize that if the relationship between the number of reads in a series of diluted samples is linear (e.g., a 10-fold dilution results in an approximately 10-fold reduction in the number of sequencing reads, a 100-fold dilution results in a 100-fold reduction in the number of sequencing reads, etc.), then the number of sequencing reads can be used to relatively quantify different targets present in the samples (e.g., relatively quantify high and low concentrations of targets). For example, if a first sequenced nucleic acid has 10 sequencing reads and a second has 100 sequencing reads, then in this scenario it can be concluded that the second nucleic acid is 10 times more concentrated than the first nucleic acid. This can be used, for example, to detect gene duplications and / or to determine the copy number of genes in a genome. Nevertheless, this approach is only relative, and as a result, the concentration of the first or second nucleic acid cannot be determined, since there is no known absolute concentration of the nucleic acid that can be used as a reference. As a result, this approach is not very accurate.For example, if the difference between high and low concentration detection is large (e.g., several orders of magnitude), resolution at low and / or high concentrations may be lost, resulting in a reduction in the fold difference between high and low compared to the true difference. This approach is also not very specific due to the fact that it is only relative and sample / sequencing run specific, and does not account for intra- and inter-laboratory variations.

[0007] Another common approach to quantification is to quantify the nucleic acids in the sample used for NGS in separate reactions. For example, quantitative PCR (qPCR) can function for absolute quantification, often using a calibration curve approach. In this approach, a calibration curve is created by plotting the crossing point (Cp) values ​​obtained from real-time PCR against a single reference template of known amount, providing a regression line that can be used to estimate the amount of the same target gene in the target sample. A serial dilution (illustratively, 10-fold dilution) of the reference template is set up with the sample containing the specific gene target that needs to be quantified. A number of separate reactions are performed, usually one for each level of the reference target and one for each target sample. Also, because assay-specific PCR efficiency differences often affect quantification, separate calibration curves using separate reference templates can be set up for different gene targets.

[0008] However, the power of NGS lies in its massive parallelism - i.e., 10s to 100s to 1000s of samples can be processed simultaneously and in parallel. Using qPCR to quantify targets can be a challenge in this scenario. Although quantification of 100s to 1000s of targets in separate nucleic acid reactions has been performed using qPCR (see, for example, High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number, Hindson et al., Anal Chem. 2011 Nov 15;83(22):8604-8610), this approach is technically challenging and requires special equipment. Also, qPCR approaches generally assume or require that the assay has identical PCR efficiency in singleplex and multiplex reactions, which may not be the case. Furthermore, all standard curve-based quantification approaches published to date require setting up external reactions and standard curve calculations.

[0009] Another approach to quantify nucleic acids in NGS uses assay-specific competitive templates (see, for example, US2015 / 0292001). Such methods aim to provide reproducibility in the measurement of nucleic acid copy numbers in samples by relying on the proportionality of native target sequences to respective competitive internal amplification controls specifically designed for the native target sequences. The competitive templates described in US2015 / 0292001 are identical priming sites to the native target nucleic acid templates, but use (e.g., artificial) interprimer sequences designed to mimic the kinetics of native targets in PCR reactions and control for target-specific variations in PCR efficiency. However, as a result, such approaches are assay and target template specific (i.e., the competitive templates are target and sample specific). To use the method described in US2015 / 0292001, it is necessary to design new competitive internal amplification controls for each new assay and / or template to be sequenced, which limits the general applicability of this approach. Furthermore, the target generally needs to be sequenced with and without the competitor template in order to deconvolute only the target's sequencing response from the target+competitor template sequencing response, which adds a level of complexity to the approach and has the potential to introduce errors into the calculations. Summary of the Invention [Problem to be solved by the invention]

[0010] Therefore, there is a need in the art for a universal internal quantification standard and a relevant quantification method for NGS. Because purification of nucleic acids from patient samples is integrated into the NGS workflow, the effects of sample-driven variability in nucleic acid extraction and the effect of any sample-derived inhibitors on PCR (and thus quantification) cannot be easily approximated by an external calibration curve. [Means for solving the problem]

[0011] The present disclosure provides a method, system, and kit for a universal internal standard that can provide simultaneous quantification of multiple target species and also considers the effect of assay-specific and matrix-derived variance in sequencing performance.Because the standard is a universal standard, it is not target, sample, or assay specific, and therefore the standard, method, and kit described herein can be used in any sequencing assay (e.g., NGS assay).The present disclosure also teaches the use of process control and / or limit of detection (LOD) control(s) for assay-specific correction.

[0012] In one aspect of the present disclosure, a method for normalizing the read value of sequencing assay is disclosed.The method includes the steps of providing a sample that contains one or more unknown nucleic acids to be sequenced; adding a known amount of internal quantification standard (IQS) to the sample; preparing the sample that contains the internal quantification standard for sequencing; sequencing to produce a sequencing data set for the sample, where the sequencing data set includes the sequencing reads observed from unknown nucleic acid(s) and internal quantification standard; counting the number of sequencing reads in the sequencing data set that originate from unknown nucleic acid(s) and internal quantification standard; and normalizing the sequencing data set, where normalizing (1) applies a data pass / fail criterion to the sequencing data set based on the presence of a minimum number of sequencing reads for the internal quantification standard for the sample (e.g., the normalized number of sequencing reads is maintained) and (2) ensures that substantially the same limit of detection (LOD) is applied to all unknown nucleic acids in the sequencing assay. In one embodiment, preparing a sample with an internal quantification standard for sequencing may include introducing a sequencing primer binding site and a sample-specific identification sequence into unknown nucleic acid in the sample and the internal quantification standard.In another embodiment, preparing a sample with an internal quantification standard for sequencing may include one or more of the following steps: lysis of cells in the sample, recovery of nucleic acid from the lysate, nucleic acid purification, a first multiplex PCR using a target-specific primer with an overhang, a second nucleic acid purification, a second multiplex PCR using a sample-specific sequencing adapter primer, a third nucleic acid purification, and pooling a plurality of similarly prepared samples for sequencing.Since the standard is added at the beginning of sample preparation, the standard is carried through all steps, and systematic loss and efficiency are accounted for for all steps.

[0013] In one embodiment, each unknown nucleic acid in the sample is about 0 to 10 13 The unknown nucleic acid may have a concentration of 10 copies / ml - i.e., in some cases, there may be no unknown nucleic acid (0 copies / ml) or the concentration of the unknown nucleic acid may be very high (e.g., 10 13 In a typical sample, the concentration of the unknown nucleic acid is approximately 10 3 ~10 9 In one embodiment, the known amount of IQS added to the sample may be in the range of about 10 4 ~10 6 copies / ml (e.g., approximately 5 × 10 5 Copies / ml). Depending on or to affect the limit of detection (LOD), more or less IQS may be added to the sample. In one embodiment, one type of IQS may be added to the sample. In another embodiment, two or more types of IQS may be added to the sample at different input concentrations so that a calibration curve can be created for quantification using two or more reference points.

[0014] In one embodiment, there can preferably be a linear relationship between the amount of internal quantification standard added to sample and the number of sequencing reads related to internal quantification standard.That is, the number of sequencing reads caused by internal quantification standard does not have to be equal to the input amount of internal quantification standard, but the number of reads should be linearly related to the input amount.If the relationship is not linear, it can be interpreted as an indication that there is a problem with one or more of the internal quantification standard added, sample preparation, or sequencing.

[0015] In one embodiment, normalization maintains a normalized number of sequencing reads (NORM), where NORM=number of sequencing reads*(F / number of observed sequencing reads derived from internal quantification standard). "F" is a user-set normalization factor that defines a fixed, minimum expected number of IQS sequencing reads. In one embodiment, the value of F can be assay-specific. "F" is a value of the number of sequencing reads that is set to ensure sufficient sequencing read depth for the limit of detection (LOD) of the sequencing assay. NORM may represent a subset of the sequencing data, and is the number of sequencing reads that are stored for further analysis and quantification. For example, if the number of observed sequencing reads derived from the internal quantification standard is the same as "F", NORM is equal to the number of sequencing reads recorded. On the other hand, if the number of sequencing reads of the internal quantification standard in the data set is greater than "F", NORM downscales the data to account for the over reads to ensure that the same LOD applies across all samples. If the number of sequencing reads of the internal quantification standard in the data set is less than "F", the data from that sample may be rejected. In one embodiment, the data may be normalized by the relationship ALPHA, where the unknown nucleic acid reads and the internal quantification standard reads are each separately normalized by the same ratio ALPHA, where ALPHA=F / the number of observed sequencing reads from the internal quantification standard.

[0016] In one embodiment, the sequencing read depth is in the range of about 1000 internal quantification standard sequencing reads to about 100,000 internal quantification standard sequencing reads, preferably about 2000 internal quantification standard sequencing reads to about 75,000 internal quantification standard sequencing reads, more preferably about 5000 internal quantification standard sequencing reads to about 50,000 internal quantification standard sequencing reads, or most preferably at least 5000 internal quantification standard sequencing reads. If fewer than "F" sequencing reads are recorded against the internal quantification standard, data for samples associated with insufficient "F" read counts may be rejected.

[0017] In one embodiment, the method may include calculating the input quantity (IQT) of an unknown nucleic acid in the sample after normalization, where the input quantity of the internal quantification standard is known, so the input quantity (IQT) of the unknown nucleic acid can be calculated by IQT=normalized number of unknown nucleic acid sequencing reads attributable to the unknown nucleic acid*(input quantity of internal quantification standard / F). In one embodiment, the method may include calculating the input quantity of two or more unknown nucleic acids in the sample by calculating the input quantity (IQTi, IQTj, IQTk...IQTn) of the multiple unknown nucleic acids, if present, in the sample after normalization as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input quantity of internal quantification standard / F).

[0018] In one embodiment, two or more samples may be pooled before subjecting them to sequencing. In one embodiment, samples may be pooled after individual samples have been prepared for sequencing, but before the actual sequencing. In one embodiment, 2-1000 samples may be pooled after preparation and before sequencing, preferably 2-500 samples may be pooled after preparation and before sequencing, more preferably 2-100 samples may be pooled after preparation and before sequencing, more preferably 2-50 samples may be pooled after preparation and before sequencing, or most preferably 2-32 samples may be pooled after preparation and before sequencing. The number of samples that can be pooled for sequencing is generally limited only by the ability to distinguish between samples in the resulting data. For example, samples in a pool may be distinguished by sample-specific sequencing adaptor primers used to identify sequencing data derived from specific samples. In this example, the distinction may be limited by the length and diversity of the sequencing adaptor primers.

[0019] In one embodiment, each pooled sample has a unique set of sample-specific identification sequences associated therewith, thereby allowing the sequencing data from each sample in the pool to be distinguished and separated.In one embodiment, each pooled sample has its own internal quantification standard associated with its own unique set of sample-specific identification sequences, where normalization is applied separately to each sample in the pool.In one embodiment, normalization applies (1) data pass / fail criteria to each sample in the pool separately, and (2) ensures that substantially the same limit of detection (LOD) is applied to all unknown nucleic acids in each sample.

[0020] In one embodiment, the method may include calculating the input quantity (IQT) of the unknown nucleic acid in each sample after the data from each sample is normalized. Since the input quantity of the internal quantification standard in each sample is known, the input quantity (IQT) of the unknown nucleic acid can be calculated. The input quantities (IQTi, IQTj, IQTk···IQTn) of the multiple unknown nucleic acids in the pooled sample can be calculated after normalization as IQTn=normalized number of unknown "n" nucleic acid sequencing reads from the "nth" unknown nucleic acid*(input quantity of internal quantification standard / F).

[0021] In one embodiment, preparing the sample(s) for sequencing may include lysing the sample to produce a lysate, recovering nucleic acids from the lysate (the recovered nucleic acids may be purified), and introducing primer binding sites and sample-specific identification sequences to the regions of the nucleic acids to be sequenced. The attachment may include one of amplifying the nucleic acids to be sequenced in an amplification reaction with target-specific primers having dual-indexed sequencing overhangs that include a sequencing primer binding site and a sample-specific identification sequence, or fragmenting the nucleic acids to be sequenced and ligating sequencing-specific adapters that include a sequencing primer binding site and a sample-specific identification sequence to the fragmented nucleic acids.

[0022] In one embodiment, amplifying the nucleic acid to be sequenced may include performing a first multiplex PCR reaction with target-specific primers having custom overhangs, performing a first nucleic acid purification, performing a second PCR reaction with a dual-indexed sequencing adapter primer that anneals or ligates to the custom overhangs introduced in the first PCR, and performing a second nucleic acid purification. In one embodiment, the dual-indexed sequencing adapter primer is target-independent and comprises a sequencing primer binding site and a sample-specific identification sequence.

[0023] In one embodiment, the amplification may be performed to limit or compress the upper end of the dynamic range of the concentration of nucleic acids in the sample to be sequenced. This may reduce the burden of sequencing and data analysis, and may reduce the number of cases in which only highly enriched nucleic acids appear in the sequencing data set. In one embodiment, the amplification may include limiting one or more of the cycle number or the concentration of the target-specific primer in the first multiplex PCR reaction to plateau the amplification of nucleic acids present at concentrations higher than the desired dynamic range, for example, compression is performed to limit the dynamic range of nucleic acids to about 10 7 The plateau concentration may be reduced to 10 copies / ml, whereas the plateau concentration may be reduced to 10 7 Nucleic acids present at less than copies / ml are present in the concentration range of the exponential amplification stage. In other embodiments, amplification can be used to limit or compress other parts of the dynamic range. For example, if only high concentration species are of interest in a sequencing assay, then higher concentration nucleic acids (e.g., >10 5 Amplification may be limited so that only 100 copies / ml are observed.

[0024] In embodiments of any of the aforementioned methods, the sequencing assay may be a next generation sequencing assay.

[0025] In another aspect, a method for performing a quantitative next generation sequencing (NGS) assay is disclosed, the method comprising providing a sample containing one or more unknown nucleic acids to be sequenced, where the unknown nucleic acids are about 0-10 13 spiking the sample with a known amount of IQS, said known amount being about 10 copies / ml (depending on the intended dynamic range of the assay); 4 ~10 6 copies / ml; preparing a sample including the internal quantification standard for sequencing; sequencing the unknown nucleic acid and the internal quantification standard in the sample to produce sequencing data; counting the number of sequencing reads in a sequencing dataset that are derived from the unknown nucleic acid(s) and the internal quantification standard; and normalizing the sequencing dataset and calculating the input quantity (IQT) of the unknown nucleic acid in by IQT = normalized number of unknown nucleic acid sequencing reads derived from the unknown nucleic acid * (input quantity of internal quantification standard / F), where "F" is a fixed minimum expected number of sequencing reads of the internal quantification standard.

[0026] In one embodiment, the normalizing step may include maintaining a normalized number of sequencing reads (NORM), where NORM = number of sequencing reads * (F / number of observed sequencing reads derived from an internal quantification standard). Normalization separately (1) applies data pass / fail criteria to each sample in the assay, and (2) ensures that substantially the same limit of detection (LOD) is applied to all unknown nucleic acids in each sample.

[0027] In one embodiment, the unknown nucleic acid is about 10 1 ~10 12 copies / ml or, preferably, about 10 1 ~10 9 In one embodiment, "F" refers to the LOD of the assay. For example, about 10 5For IQS input concentration in copies / ml, "F" is approximately 10 2 ~10 3 Then, the LOD for the unknown nucleic acid in the sample is about 10 3 ~10 2 copies / ml. For IQS with the same input concentration, "F" is approximately 10 3 ~10 4 (i.e., as the read depth increases and the weight of each read increases accordingly), the LOD for the unknown nucleic acid in the sample is approximately 10 2 ~10 1 For a given input concentration of IQS, the LOD can be raised or lowered by increasing or decreasing the read depth (i.e., by increasing or decreasing the degree of "F") and, correspondingly, by increasing or decreasing the weight attributed to each individual sequencing read.

[0028] In one embodiment, a method for performing a quantitative next generation sequencing (NGS) assay may include calculating the input amounts (IQTi, IQTj, IQTk···IQTn) of multiple unknown nucleic acids, if present, in a sample as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0029] In one embodiment, a method for performing quantitative next-generation sequencing (NGS) assays can include pooling two or more samples and subjecting them to sequencing simultaneously, where two or more samples are prepared and pooled before sequencing.In one embodiment, each pooled sample can have a unique set of sample-specific identification sequences associated with it, thereby allowing the sequencing data from each sample in the pool to be distinguished and separated.In one embodiment, each pooled sample can have a unique internal quantification standard associated with a unique set of sample-specific identification sequences, where quantification is applied separately to each nucleic acid from each sample in the pool.Normalization and quantification can be applied to multiple nucleic acids in multiple samples in the same way as multiple nucleic acids in one sample described above. The method includes calculating the input amounts (IQTi, IQTj, IQTk···IQTn) of multiple unknown nucleic acids in the pooled sample as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0030] In one embodiment, a method for performing a quantitative next-generation sequencing (NGS) assay may include providing a set of assay-specific positive controls to be sequenced, where the positive controls include positive controls corresponding to each of one or more unknown nucleic acids to be sequenced in the assay. In one embodiment, a method for performing a quantitative next-generation sequencing (NGS) assay may include applying an assay-specific correction factor to each of one or more unknown nucleic acids based on the sequence read number of the assay-specific positive control. If the efficiency of PCR amplification is not perfect, or if the efficiency of the target and the internal standard are different, the correction factor may depend on the amount of positive control input into the reaction. Thus, in one embodiment, the amount of positive control should be in the middle of the intended dynamic range of the corresponding target.

[0031] In yet another aspect, a kit for normalizing and quantifying unknown nucleic acids in a next generation sequencing (NGS) assay is described. The kit may include an internal quantification standard (IQS), where the IQS is a nucleic acid configured to be added in a known amount to a sample containing an unknown nucleic acid to be sequenced; and instructions for using the IQS to normalize a sequencing data set and to calculate the input amount of the unknown nucleic acid. In one embodiment, the kit may include a set of IQSs that are added at different known concentrations to create a standard curve for the quantification of the unknown nucleic acid. In one embodiment, the IQS provided in the kit is about 10 4 ~10 6 The amount of IQS(s) may be increased or decreased to expand or compress the upper and lower limits of the detection range, although it may be configured to be added to the sample in the range of copies / ml. In one embodiment, the internal quantification standard is used to normalize the sequencing data to maintain a normalized number of sequencing reads (NORM), where NORM=number of sequencing reads*(F / number of observed sequencing reads derived from the internal quantification standard), where "F" is the fixed minimum expected number of sequencing reads of the internal quantification standard, and the input amount of unknown nucleic acid (IQT) is calculated using the internal quantification standard by IQT=normalized number of unknown nucleic acid sequencing reads derived from the unknown nucleic acid*(input amount of internal quantification standard / F).

[0032] In one embodiment, the kit further comprises a sequencing-specific adaptor for at least an internal quantification standard, the adaptor comprising a sequencing adaptor site and a sample-specific identification sequence. In one embodiment, the kit may further comprise a target-specific primer with a custom overhang configured for amplification of the internal quantification standard and annealing or ligation to the sequencing-specific adaptor.

[0033] In yet another embodiment, a method for performing a comparator test is described. The method for performing a comparator test may include: providing a first assay, which comprises single or multiplex amplification and detection of one or more target nucleic acids (the first assay has a limit of detection (LOD)), and providing a second assay, different from the first assay, to confirm the detection and LOD of the first assay. The second assay should have at least the same LOD as the first assay, but may have a lower LOD. In one or more embodiments, the second assay may include: preparing a sample for sequencing including at least one internal quantification standard; sequencing to produce a sequencing dataset for the sample, where the sequencing dataset includes sequencing reads observed from the target nucleic acid(s) and the internal quantification standard; counting the number of sequencing reads in the sequencing dataset derived from the target nucleic acid(s) and the internal quantification standard; and normalizing the sequencing dataset, where normalizing (1) applies a data pass / fail criterion to the sequencing dataset based on the presence of a minimum number of sequencing reads for the internal quantification standard for the sample, and (2) ensures that a substantially identical limit of detection (LOD) is applied to all unknown nucleic acids in the sequencing assay, where the LOD of the second assay is substantially the same as the LOD of the first assay.

[0034] In one embodiment, the first assay may be a qualitative molecular diagnostic assay. In another embodiment, the first assay may be a semi-quantitative molecular diagnostic assay. In one embodiment, the first assay may further comprise adding one or more internal quantification standards to the sample and performing a quantitative two-step amplification. In one embodiment, the quantitative two-step amplification comprises: amplifying the sample in a first-stage multiplex amplification mixture, where the amplification mixture comprises a plurality of target primers and at least one quantification standard primer pair, where each target primer pair is configured to amplify a different target that may be present in the sample, and the quantification standard primer pair is configured to amplify an internal quantification standard nucleic acid; splitting the first-stage amplification mixture into a plurality of second-stage individual reactions, where a first group of the plurality of second-stage individual reactions comprises at least one quantification standard primer pair configured to further amplify one of the different targets that may be present in the sample. a second group of the plurality of second-stage individual reactions each comprising at least one primer pair configured to further amplify one of the internal quantification standard nucleic acids; and subjecting the plurality of second-stage individual reactions to amplification conditions to produce one or more target amplicons and a plurality of quantification standard amplicons, each having a related quantification standard crossing point (Cp), where each target nucleic acid has a Cp and each internal standard has a known concentration in the first assay and a known quantification standard Cp.

[0035] In one embodiment, the method may further comprise the steps of: generating a standard curve from the crossing points (Cp) of two or more quantification standards in the first assay; and quantifying each of the one or more target nucleic acids using the standard curve. In one embodiment, each of the target nucleic acids comprises: log 10 (concentration)=(Cp-b) / a may be quantified in the first assay using a standard curve generated using a least squares regression line fitted to where Cp is the crossing point measured for each target and b (the intercept) is the log 10 represents the Cp value when (concentration) is zero, and a is the slope, which represents the degree to which Cp changes with a single unit change in concentration.

[0036] In one embodiment, the second assay may further comprise normalizing the sequencing data set to maintain NORM sequencing reads, where NORM=number of sequencing reads*(F / number of observed sequencing reads derived from internal quantification standard). In one embodiment, the nucleic acids in the second assay may be quantified by calculating the input quantity (IQT) of each target nucleic acid in the sample by IQT=normalized number of target nucleic acid sequencing reads derived from the target nucleic acid*(input quantity of internal quantification standard / F), where "F" is the fixed minimum expected number of sequencing reads of the internal quantification standard. The same principle applies to the calculation of the input concentration of multiple unknown nucleic acids in a sample. The input amounts of multiple target nucleic acids, if present, in a sample (IQTi, IQTj, IQTk···IQTn) can be calculated as IQTn=normalized number of unknown “n” nucleic acid sequencing reads attributable to the “nth” unknown nucleic acid*(input amount of internal quantification standard / F).

[0037] In one embodiment, the "F" in the second assay may relate to the limit of detection (LOD) of the second assay. The LOD of the second assay is selected to be substantially the same as the LOD of the first assay. In one embodiment, the "F" relates to the LOD of the assay. For example, about 10 5 For IQS input concentration in copies / ml, "F" is approximately 10 3 Then, the LOD for the unknown nucleic acid in the sample is about 10 2 copies / ml. For IQS with the same input concentration, "F" is approximately 10 4(i.e., as read depth increases and the weight of each read correspondingly increases), the LOD for the unknown nucleic acid in the sample is approximately 10 copies / ml. For an IQS at a given input concentration, the LOD can be raised or lowered by increasing or decreasing the read depth (i.e., by increasing or decreasing the degree of "F") and, correspondingly, by increasing or decreasing the weight attributed to each individual sequencing read.

[0038] In one embodiment, the method for performing a comparator test may include pooling two or more samples and subjecting them to sequencing simultaneously, where the two or more samples are pooled after preparation and before sequencing. In one embodiment, each pooled sample may have a unique set of sample-specific identification sequences associated therewith, thereby allowing for distinguishing and separating the sequencing data from each sample in the pool. In one embodiment, each pooled sample may have its own internal quantification standard associated with its own unique set of sample-specific identification sequences. As described above for multiple nucleic acids in one sample, normalization and quantification may be applied to multiple nucleic acids in multiple pooled samples. The method includes calculating the input amount (IQTi, IQTj, IQTk···IQTn) of multiple unknown nucleic acids in a pooled sample as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributed to "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0039] In any of the foregoing embodiments, the sequencing assays, methods, and kits described herein do not include a step of performing relative quantification, i.e., the sequencing assays, methods, and kits described herein include an internal quantification standard of known concentration, so that it is not necessary to rely on the relative number of sequencing reads or the relative abundance of detected nucleic acids to determine the relative concentration of unknowns.

[0040] In any of the above-mentioned embodiments, the sequencing assays, methods and kits described herein do not include a step of performing quantification in a reaction separate from the sequencing assay.That is, the sequencing assays, methods and kits described herein include an internal quantification standard of known concentration, so there is no need to perform a separate reaction (e.g., qPCR) to determine the input concentration of nucleic acid in the sequencing reaction.

[0041] In any of the above-mentioned embodiments, the sequencing assay, method and kit described herein do not include the step of using assay or template-specific quantification standard.That is, instead of relying on the standard designed for specific assay or specific target, the sequencing assay, method and kit described herein include a universal internal standard, which can provide simultaneous quantification of multiple target species in any sequencing assay (e.g., NGS assay).

[0042] In any of the above-mentioned embodiments, the sequencing assay, method and kit described herein do not include the step of using competitive template as quantification standard.Generally, competitive template is a specific type of quantification standard specific to assay or template.However, new competitive internal amplification control needs to be designed for each new assay and / or template to be sequenced.Instead, the sequencing assay, method and kit described herein include a universal internal standard that can provide simultaneous quantification of multiple target species in any sequencing assay (e.g. NGS assay).

[0043] Described herein are: A1. A method for normalization of read values ​​of a sequencing assay, comprising the steps of: Providing a sample containing one or more unknown nucleic acids to be sequenced; adding a known amount of an internal quantification standard to the sample; preparing a sample for sequencing that includes an internal quantification standard, where the preparing step includes introducing a sequencing-specific adapter site and a sample-specific identification sequence to unknown nucleic acids in the sample and the internal quantification standard; sequencing to produce a sequencing dataset for the sample, where the sequencing dataset includes observed sequencing reads from the unknown nucleic acid(s) and the internal quantification standard; Counting the number of sequencing reads in the sequencing dataset derived from the unknown nucleic acid(s) and the internal quantification standard; and Normalizing the sequencing dataset, where normalization involves (1) applying a data pass / fail criterion to the sequencing dataset based on the presence of a minimum number of sequencing reads relative to the internal quantification standard for the sample, and (2) ensuring that substantially the same limit of detection (LOD) is applied to all unknown nucleic acids in the sequencing assay.

[0044] A2. The method of clause A1, wherein each unknown nucleic acid in the sample is about 0 to 10 13 copies / ml (e.g., about 10 2 ~10 9 The antibody has a concentration of 100 copies / ml.

[0045] A3. At least one of the methods of clause A1 or clause A2, wherein the known amount of the internal quantification standard added to the sample is about 10 3 ~10 6 copies / ml (e.g., about 10 5 ~10 6 copies / ml).

[0046] A4. The method or methods of clauses A1-A3, wherein a linear relationship exists between the known amount of the internal quantification standard added to the sample and the number of sequencing reads for the internal quantification standard.

[0047] A5. The method of any one or more of clauses A1-A4, wherein normalizing the sequencing dataset comprises maintaining NORM sequencing reads, where NORM=number of sequencing reads*(F / number of observed sequencing reads derived from the internal quantification standard), where "F" is a fixed minimum expected number of sequencing reads for the internal quantification standard.

[0048] A6. The method of any one or more of clauses A1-A5, wherein "F" is a value of the number of sequencing reads set to ensure sufficient sequencing read depth for the LOD of the sequencing assay.

[0049] A7. The method of any one or more of clauses A1 to A6, wherein the sequencing read depth is in the range of about 1000 internally quantified standard sequencing reads to about 100,000 internally quantified standard sequencing reads, preferably about 2000 internally quantified standard sequencing reads to about 75,000 internally quantified standard sequencing reads, more preferably about 5000 internally quantified standard sequencing reads to about 50,000 internally quantified standard sequencing reads, or most preferably at least 5000 internally quantified standard sequencing reads.

[0050] A8. The method of any one or more of clauses A1-A7, wherein the reads of the unknown nucleic acid and the reads of the internal quantification standard are each separately normalized by the same ratio ALPHA, where ALPHA=F / number of observed sequencing reads derived from the internal quantification standard.

[0051] A9. The method of any one or more of clauses A1-A8, further comprising calculating an input quantity (IQT) of the unknown nucleic acid in the sample after normalization, where the input quantity of the internal quantification standard is known and therefore the input quantity (IQT) of the unknown nucleic acid can be calculated by IQT = normalized number of unknown nucleic acid sequencing reads attributable to the unknown nucleic acid * (input quantity of internal quantification standard / F).

[0052] A10. The method of any one or more of clauses A1-A9, further comprising calculating the input amount (IQTi, IQTj, IQTk···IQTn) of a plurality of unknown nucleic acids, if present, in the sample after normalization, as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0053] A11. The method of any one or more of clauses A1-A10, wherein preparing the sample includes sample lysis, recovering nucleic acid from the lysate, and optionally purifying the recovered nucleic acid, and attaching or introducing a primer binding site and a sample-specific discrimination sequence within the region of the nucleic acid to be sequenced.

[0054] A12. The method of any one or more of clauses A1-A11, wherein the attaching step comprises: amplifying the nucleic acid to be sequenced in an amplification reaction using a target-specific primer having a dual-indexed sequencing overhang that includes a sequencing primer binding site and a sample-specific identification sequence; or Fragmenting the nucleic acid to be sequenced and ligating a sequencing-specific adapter comprising a sequencing primer binding site and a sample-specific identification sequence to the fragmented nucleic acid. Contains one of the following:

[0055] A13. The method of any one or more of clauses A1 to A12, wherein the step of amplifying the nucleic acid to be sequenced comprises: performing a first multiplex PCR reaction using target-specific primers with custom overhangs; performing a first nucleic acid purification; performing a second PCR reaction with a dual-indexed sequencing adapter primer that anneals or ligates to the overhangs introduced in the first PCR, where the dual-indexed sequencing adapter primer is target-independent and comprises a sequencing primer binding site and a sample-specific identification sequence; performing a second nucleic acid purification; Includes.

[0056] A14. Any one or more methods of clauses A1 to A13, 7 To plateau the amplification of nucleic acids present at concentrations greater than 10 copies / ml and to achieve approximately 10 in the exponential amplification phase. 7 The method further comprises limiting one or more of the number of cycles or the concentration of target-specific primers in the first multiplex PCR reaction to conserve less than copies / ml of nucleic acid.

[0057] A15. The method of any one or more of clauses A1-A14, further comprising pooling two or more samples and subjecting them to sequencing simultaneously, wherein the two or more samples are pooled after preparation and prior to sequencing.

[0058] A16. The method of any one or more of clauses A1-A15, wherein between 2 and 1000 samples are pooled after preparation and before sequencing, preferably between 2 and 500 samples are pooled after preparation and before sequencing, more preferably between 2 and 100 samples are pooled after preparation and before sequencing, more preferably between 2 and 50 samples are pooled after preparation and before sequencing, or most preferably between 2 and 32 samples are pooled after preparation and before sequencing.

[0059] A17. The method of any one or more of clauses A1-A16, wherein each pooled sample has associated therewith a unique set of sample-specific discriminator sequences, thereby enabling differentiation and separation of sequencing data from each sample within the pool.

[0060] A18. The method of any one or more of clauses A1-A17, wherein each pooled sample has a unique internal quantification standard associated with a unique set of sample-specific discriminator sequences, and wherein normalization is applied separately to each sample in the pool.

[0061] A19. The method of any one or more of clauses A1-A18, wherein normalization separately (1) applies data pass / fail criteria to each sample in the pool, and (2) ensures that substantially the same limit of detection (LOD) is applied to all unknown nucleic acids in each sample.

[0062] A20. The method of any one or more of clauses A1-A19, further comprising calculating, after normalization, the input amounts (IQTi, IQTj, IQTk···IQTn) of the multiple unknown nucleic acids in the pooled samples as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0063] A21. The method of any one or more of clauses A1-A20, wherein the sequencing assay is a next-generation sequencing assay.

[0064] A22. The method of any one or more of clauses A1-A21, wherein the sequencing assay does not include a step of performing relative quantification.

[0065] A23. The method of any one or more of clauses A1-A22, wherein the sequencing assay does not include a step of performing quantification in a reaction separate from the sequencing assay.

[0066] A24. The method of any one or more of clauses A1-A23, wherein the sequencing assay does not include a step of using an assay- or template-specific quantification standard.

[0067] A25. The method of any one or more of clauses A1-A24, wherein the sequencing assay does not include a step of using a competing template as a quantification standard.

[0068] B1. A method for performing a quantitative next generation sequencing (NGS) assay, comprising the steps of: Providing a sample containing one or more unknown nucleic acids to be sequenced; adding a known amount of an internal quantification standard to the sample; preparing samples containing an internal quantification standard for sequencing; sequencing the unknown nucleic acids in the sample and the internal quantification standard to produce sequencing data; Counting the number of sequencing reads in the sequencing dataset derived from the unknown nucleic acid(s) and the internal quantification standard; and Normalizing the sequencing dataset and calculating the input quantity (IQT) of the unknown nucleic acid in by IQT = normalized number of unknown nucleic acid sequencing reads derived from the unknown nucleic acid * (input quantity of internal quantification standard / F), where "F" is a fixed minimum expected number of sequencing reads of the internal quantification standard.

[0069] B2. The method of clause B1, wherein each unknown nucleic acid in the sample is about 0 to 10 13 copies / ml (e.g., about 10 2 ~10 9 The antibody has a concentration of 100 copies / ml.

[0070] B3. At least one of the methods of clause B1 or clause B2, wherein the known amount of internal quantification standard added to the sample is about 10 4 ~10 6 copies / ml (e.g., about 10 5 ~10 6 copies / ml).

[0071] B4. Any one or more methods of clauses B1-B3, further comprising normalizing the sequencing dataset by NORM=number of sequencing reads*(F / number of observed sequencing reads derived from an internal quantification standard).

[0072] B5. The method of any one or more of clauses B1-B4, wherein normalization separately (1) applies data pass / fail criteria to each sample in the assay, and (2) ensures that substantially the same limit of detection (LOD) applies to all unknown nucleic acids in each sample across multiple samples pooled together and used across multiple users, days, etc.

[0073] B6. The method of any one or more of clauses B1-B5, wherein the unknown nucleic acid is about 10 2 ~10 10 copies / ml or, preferably, about 10 2 ~10 9It has a concentration of copies / ml.

[0074] B7. The method of any one or more of clauses B1-B6, wherein "F" refers to the limit of detection (LOD) of the NGS assay, wherein "F" is about 1×10 3 ~5×10 3 Then, the LOD for the unknown nucleic acid is about 10 2 ~10 3 copies / ml.

[0075] B8. The method of any one or more of clauses B1-B7, wherein "F" refers to the limit of detection (LOD) of the NGS assay, wherein "F" is about 1×10 4 ~5×10 4 Then, the LOD for the unknown nucleic acid is about 10 1 ~10 2 copies / ml.

[0076] B9. The method of any one or more of clauses B1-B8, further comprising calculating the input amounts (IQTi, IQTj, IQTk···IQTn) of a plurality of unknown nucleic acids, if present, in the sample as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0077] B10. The method of any one or more of clauses B1-B9, further comprising pooling two or more samples and subjecting them to sequencing simultaneously, wherein the two or more samples are pooled after preparation and prior to sequencing.

[0078] B11. The method of any one or more of clauses B1-B10, wherein each pooled sample has associated therewith a unique set of sample-specific discriminatory sequences, thereby enabling differentiation and separation of sequencing data from each sample within the pool.

[0079] B12. The method of any one or more of clauses B1-B11, wherein each pooled sample has a unique internal quantification standard associated with a unique set of sample-specific discriminatory sequences, wherein quantification is applied separately to each nucleic acid from each sample in the pool.

[0080] B13. The method of any one or more of clauses B1-B12, further comprising calculating the input amounts (IQTi, IQTj, IQTk···IQTn) of the multiple unknown nucleic acids in the pooled samples as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0081] B14. The method of any one or more of clauses B1-B13, further comprising providing a set of assay-specific positive controls in the sample to be sequenced, wherein the positive controls include a positive control corresponding to each of the one or more unknown nucleic acids to be sequenced in the assay.

[0082] B15. The method of any one or more of clauses B1-B14, further comprising applying an assay-specific correction factor to each of the one or more unknown nucleic acids based on sequencing of the assay-specific positive control.

[0083] B16. The method of any one or more of clauses B1-B15, wherein performing a quantitative NGS assay does not include performing relative quantification.

[0084] B17. The method of any one or more of clauses B1-B16, wherein performing the quantitative NGS assay does not include performing the quantification in a reaction separate from the sequencing assay.

[0085] B18. The method of any one or more of clauses B1-B17, wherein performing the quantitative NGS assay does not include using an assay- or template-specific quantification standard.

[0086] B19. The method of any one or more of clauses B1-B18, wherein performing a quantitative NGS assay does not include using a competitive template as a quantification standard.

[0087] C1. A kit for normalizing and quantifying unknown nucleic acids in a next generation sequencing (NGS) assay, comprising: An internal quantification standard, where the internal quantification standard is a nucleic acid that is configured to be added in a known amount to a sample containing the unknown nucleic acid to be sequenced; and Instructions for the use of an internal quantification standard to normalize sequencing datasets and to calculate input amounts of unknown nucleic acids; Here, the internal quantification standard is approximately 10 4 ~10 6 configured to be added to a sample in the range of copies / ml; where, using an internal quantification standard, the sequencing data is normalized by NORM=number of sequencing reads*(F / number of observed sequencing reads derived from the internal quantification standard), where "F" is a fixed minimum expected number of sequencing reads for the internal quantification standard, and Here, using an internal quantification standard, the input quantity (IQT) of an unknown nucleic acid is calculated by: IQT = normalized number of unknown nucleic acid sequencing reads derived from the unknown nucleic acid * (input quantity of internal quantification standard / F).

[0088] C2. The kit of clause C1, further comprising a sequencing-specific adapter for at least an internal quantification standard, the sequencing-specific adapter comprising a sequencing primer binding site and a sample-specific identification sequence.

[0089] C3. At least one kit of clause C1 or clause C2, further comprising a target-specific primer with a custom overhang configured for amplification of an internal quantification standard and for annealing or ligating to a sequencing-specific adapter.

[0090] C4. At least one of the kits of clauses C1-C3, further comprising two or more internal quantification standards, wherein each of the two or more internal quantification standards is configured to be added to a sample at a different known concentration to generate a calibration curve for quantification of an unknown nucleic acid.

[0091] D1. A method for performing a comparator test, comprising the steps of: providing a first assay comprising multiplex amplification and detection of one or more target nucleic acids, the first assay having a limit of detection (LOD); providing a second assay, different from the first assay, to confirm the detection and LOD of the first assay; wherein the second assay comprises: preparing samples for sequencing that include at least one internal quantification standard; sequencing to produce a sequencing dataset for the sample, where the sequencing dataset comprises sequencing reads observed from the target nucleic acid(s) and an internal quantification standard; Counting the number of sequencing reads in the sequencing dataset derived from the target nucleic acid(s) and the internal quantification standard; and Normalizing the sequencing dataset, where normalization involves (1) applying a data pass / fail criterion to the sequencing dataset based on the presence of a minimum number of sequencing reads for the internal quantification standard for the sample, and (2) ensuring that substantially identical limit of detection (LOD) is applied to all unknown nucleic acids in the sequencing assays, where the LOD of the second assay is substantially the same as the LOD of the first assay.

[0092] D2. The method of clause D1, wherein the first assay further comprises adding one or more internal quantification standards to the sample and performing a quantitative two-step amplification on the sample, the quantitative two-step amplification comprising the steps of: amplifying the sample in a first-stage multiplex amplification mixture, where the amplification mixture comprises a plurality of target primers and at least one quantification standard primer, where each target primer is configured to amplify a different target that may be present in the sample, and where the quantification standard primer is configured to amplify an internal quantification standard nucleic acid; dividing the first-stage amplification mixture into a plurality of second-stage individual reactions, a first group of the plurality of second-stage individual reactions each including at least one primer configured to further amplify one of the distinct targets that may be present in the sample, and a second group of the plurality of second-stage individual reactions each including at least one primer configured to further amplify one of the internal quantification standard nucleic acids; and subjecting a plurality of second-stage individual reactions to amplification conditions to produce one or more target amplicons and a plurality of quantification standard amplicons, each quantification standard amplicon having an associated quantification standard Cp; Here, each target nucleic acid has a crossing point (Cp) and each internal standard has a known concentration in the first assay and a known quantification standard Cp.

[0093] D3. At least one method of clause D1 or clause D2, comprising: preparing a calibration curve from the quantification standard Cp; and Quantifying each of the one or more target nucleic acids using a standard curve. Further includes:

[0094] D4. The method of any one or more of clauses D1-D3, wherein each of the target nucleic acids is quantified using a standard curve generated using a least squares regression line fitted to: log 10 (concentration)=(Cp-b) / a where Cp is the crossing point measured for each target, b (intercept) is the log 10 represents the Cp value when (concentration) is zero, and a is the slope, which represents the degree to which Cp changes with a single unit change in concentration.

[0095] D5. The method of any one or more of clauses D1-D4, further comprising normalizing the sequencing dataset in the second assay by NORM=number of sequencing reads*(F / number of observed sequencing reads derived from an internal quantification standard).

[0096] D6. The method of any one or more of clauses D1-D5, comprising calculating the input quantity (IQT) of each target nucleic acid in the sample by: IQT=normalized number of target nucleic acid sequencing reads derived from the target nucleic acid*(input quantity of internal quantification standard / F), where "F" is a fixed minimum expected number of sequencing reads of the internal quantification standard.

[0097] D7. The method of any one or more of clauses D1-D6, wherein "F" refers to a limit of detection (LOD) of a second assay, wherein the LOD of the second assay is selected to be substantially identical to the LOD of the first assay.

[0098] D8. Any one or more of the methods of clauses D1-D7, wherein "F" is about 1×10 3 ~5×10 3 then the LOD for detection of the target nucleic acid(s) in the second assay is about 10 2 ~10 3 copies / ml.

[0099] D9. Any one or more methods of clauses D1-D, wherein "F" is about 1×10 4 ~5×10 4 then the LOD for detection of the target nucleic acid(s) in the second assay is about 10 1 ~10 2 copies / ml.

[0100] D10. The method of any one or more of clauses D1-D9, further comprising calculating the input amounts (IQTi, IQTj, IQTk···IQTn) of a plurality of target nucleic acids, if present, in the sample as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0101] D11. The method of any one or more of clauses D1-D10, further comprising pooling two or more samples in a second assay and subjecting them to sequencing simultaneously, wherein the two or more samples are pooled after preparation and prior to sequencing.

[0102] D12. The method of any one or more of clauses D1-D11, wherein each pooled sample has associated therewith a unique set of sample-specific discriminatory sequences, thereby enabling differentiation and separation of sequencing data from each sample in the pool.

[0103] D13. The method of any one or more of clauses D1-D12, wherein each pooled sample has a unique internal quantification standard associated with a unique set of sample-specific discriminatory sequences, wherein quantification is applied separately to each nucleic acid from each sample in the pool.

[0104] D14. The method of any one or more of clauses D1-D13, further comprising calculating input amounts (IQTi, IQTj, IQTk···IQTn) of the multiple unknown nucleic acids in the pooled samples as IQTn=normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid*(input amount of internal quantification standard / F).

[0105] D15. The method of any one or more of clauses D1-D14, wherein the quantification standard nucleic acids and the target nucleic acids all have similar amplification and sequencing efficiencies.

[0106] D16. The method of any one or more of clauses D1-D15, wherein the second assay is a next generation sequencing assay.

[0107] D17. The method of any one of clauses D1-D16, wherein the second assay does not include a step of performing relative quantification.

[0108] D18. The method of any one of clauses D1-D17, wherein the second assay does not include a step of quantification in a reaction separate from the sequencing assay.

[0109] D19. The method of any one of clauses D1-D18, wherein the second assay does not include a step of using an assay- or template-specific quantification standard.

[0110] D20. The method of any one of clauses D1-D19, wherein the second assay does not include using a competing template as a quantification standard.

[0111] In any of the aforementioned embodiments of the method for performing a comparator test, the second assay may be a next generation sequencing assay.

[0112] This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the drawings and detailed description. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.

[0113] Additional features and advantages will be set forth in the description which follows, and in part will be obvious based on the description, or may be learned by the practice of the invention. These and other features will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.

[0114] To illustrate the manner in which the above and other advantages and features of the invention can be obtained, a more particular description of the invention briefly described above will be given by reference to specific embodiments thereof which are illustrated in the accompanying drawings, with the understanding that these drawings represent only typical embodiments of the invention and therefore should not be considered as limiting its scope, the invention will be described and explained with additional specificity and detail through the use of the following accompanying drawings in which: [Brief description of the drawings]

[0115] [Figure 1] 1 illustrates a flexible pouch according to one embodiment of the present invention. [Diagram 2] 2A and 2B are exploded perspective views of an instrument for use with the pouch of FIG. 1, the instrument including the pouch of FIG. 1, according to an exemplary embodiment of the present invention; [Diagram 3] 3 shows a partial cross-sectional view of the device of FIG. 2 including the bladder component of FIG. 2, with the pouch of FIG. 1 shown in dashed lines, according to an exemplary embodiment of the present invention. [Figure 4] 3 shows a motor used in one illustrative embodiment of the device of FIG. 2. [Diagram 5] Cp across five dilutions of four different prospective synthetic quantification standards are shown. [Figure 6A] Similar to FIG. 5, but showing data for only three of the quantification standards. [Figure 6B] A single curve using data from all three quantification standards is shown. [Figure 7] 1 shows a calibration curve for A. baumannii plotted with a curve generated from three quantification standards, with the x-axis being the amount of A. baumannii or quantification standard contained within the reaction and the y-axis being Cp. [Figure 8A] An external calibration curve specific for A. baumannii and a composite calibration curve (uncorrected) from quantification standards are shown. [Figure 8B] The same data as in FIG. 8A is shown, with assay-specific correction factors. [Figure 9] Illustrates a hypothetical sequencing data set for three samples, A, B, and C. [Figure 10] Raw sequencing counts for the pooled sample set are shown. [Figure 11] FIG. 10 shows internal quantification standard (also referred to herein as QSM) fragment counts per sample within the pooled sample set. [Figure 12] Two alternative methods for binning and normalizing sequencing datasets are described. [Figure 13] An example of a workflow for sequencing sample preparation is described. [Figure 14] 1 shows the bacterial and / or viral load distribution in a population of saliva samples. [Figure 15]FIG. 1 shows a PCR amplification curve illustrating a method for preserving the dynamic range of a sequencing reaction, where the reaction is set up and stopped such that high copy targets are in the plateau phase and low copy targets are in the exponential amplification phase. [Figure 16] Batch positive control (PC) quantification by assay is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0116] Exemplary embodiments are described below with reference to the accompanying drawings. Many different configurations and embodiments are possible without departing from the spirit and teachings of the present disclosure, and therefore the present disclosure should not be construed as being limited to the exemplary embodiments set forth herein. Rather, these exemplary embodiments are provided so that this disclosure will be thorough and complete, and will convey the scope of the disclosure to those skilled in the art. In the drawings, the sizes and relative sizes of layers and regions may be exaggerated for clarity. Like reference numerals refer to like elements throughout the description.

[0117] Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by those of ordinary skill in the art to which this disclosure pertains. Terms such as those defined in commonly used dictionaries should be interpreted to have a meaning consistent with their meaning in the context of this application and related art, and should not be interpreted in an idealized or overly formal sense unless expressly defined herein. The terminology used in the description of the present invention herein is for the purpose of describing specific embodiments only, and is not intended to limit the present invention. Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present disclosure, only specific exemplary materials and methods are described herein.

[0118] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict in terminology, the present specification controls.

[0119] Various aspects of the disclosure, including devices, systems, methods, and the like, may be described with reference to one or more exemplary implementations. As used herein, the terms "exemplary" and "illustrative" mean "serving as an example, instance, or illustration" and should not necessarily be construed as preferred or advantageous over other implementations disclosed herein. Moreover, reference to an "implementation" or "embodiment" of the disclosure or invention includes specific reference to one or more of the embodiments, and vice versa, and is intended to provide an illustrative illustration without limiting the scope of the invention, which is indicated by the appended claims rather than the following description.

[0120] It should be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, a reference to "a tile" includes one, two, or more tiles. Similarly, a reference to a plurality of referents should be construed as including a single referent and / or multiple referents unless the content and / or context clearly dictates otherwise. Thus, a reference to "tiles" does not necessarily require a plurality of such tiles. Instead, it will be understood that one or more tiles are contemplated herein; independent of conjugation.

[0121] As used throughout this application, the words "can" and "may" are used in a permissive sense (i.e., meaning having the potential) rather than a mandatory sense (i.e., meaning a must). Further, by way of illustration, the terms "including," "having," "involving," "containing," "characterized by," variations thereof (e.g., "includes," "has," "involves," "contain," etc.) and similar terms used herein (including the claims) are inclusive and / or open-ended and have the same meaning as the word "comprising" and variations thereof (e.g., "comprise" and "comprises") and do not exclude additional, unrecited elements or method steps.

[0122] As used herein, directional and / or arbitrary terms, such as, for example, "top", "bottom", "left", "right", "up", "down", "upper", "lower", "inner", "outer", "internal", "external", "interior", "exterior", "proximal", "distal", "forward", "reverse", and the like, may be used only to indicate relative directions and / or orientations and are not otherwise intended to limit the scope of the present disclosure, including the specification, invention, and / or claims.

[0123] When an element is referred to as being "on," "coupled," "connected," or "responsive" to or on another element, it is understood that it may be directly coupled, connected, or responsive to or on the other element, or there may be intervening elements. In contrast, when an element is referred to as being "directly on," "directly coupled," "directly connected," or "directly responsive" to or on another element, there are no intervening elements present.

[0124] The exemplary embodiments of the inventive concepts are described herein with reference to cross-sectional views (and intermediate structures) that are schematic illustrations of idealized embodiments of the exemplary embodiments. As such, variations from the illustrative shapes as a result of, for example, manufacturing techniques and / or tolerances are to be expected. Thus, the exemplary embodiments of the inventive concepts should not be construed as limited to the particular shapes of the regions illustratively illustrated herein, but should include deviations in shapes that result, for example, from manufacturing. Thus, the illustrative regions in the drawings are schematic in nature, and their shapes are not intended to illustratively illustrate the actual shapes of the regions of the device, and are not intended to limit the scope of the exemplary embodiments.

[0125] It will be understood that the terms "first," "second," etc. may be used herein to describe various elements, but these elements should not be limited by these terms. These terms are used only to distinguish one element from another. Thus, a "first" element could be called a "second" element without departing from the teachings of the present embodiments.

[0126] It will also be understood that the various implementations described herein may be used in combination with any other implementations described or disclosed without departing from the scope of the present disclosure. Thus, products, components, elements, devices, apparatus, systems, methods, processes, compositions, and / or kits according to a particular implementation of the present disclosure may include, incorporate, or otherwise include properties, features, components, components, elements, steps, and / or the like described in other implementations (including systems, methods, apparatus, and / or the like) disclosed herein without departing from the scope of the present disclosure. Thus, reference to a particular feature in an implementation should not be construed as being limited to application only within said implementation.

[0127] Headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claims. To aid in understanding, like reference numbers have been used, where possible, to designate like elements common to the figures. Furthermore, like numbering of elements has been used, where possible, in the various figures. Furthermore, alternative configurations of a particular element may each include a distinct letter appended to the element number.

[0128] The term "about" is used herein to mean "approximately," "in the region of," "roughly," or "around." When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values ​​set forth. In general, the term "about" is used herein to modify numerical values ​​above and below the stated value by a variance of 5%. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values ​​are expressed as approximations, it will be understood that the particular value forms another embodiment by the use of "about" preceding it. It will be further understood that the endpoints of each range are significant in relationship to the other endpoint, and independently of the other endpoint.

[0129] As used herein, the word "or" means any one member of a particular list and also includes any combination of members of that list.

[0130] By "sample" is meant an animal; a tissue or organ from an animal; a cell (either in a subject and obtained directly from the subject, or cells maintained in culture or from a cultured cell line); a cell lysate (or lysis fraction) or cell extract; a solution containing one or more molecules (e.g., polypeptides or nucleic acids) derived from cells, cellular material, or viral material; or a solution containing nucleic acids of non-natural origin (illustratively cDNA or next generation sequencing libraries) that are assayed as described herein. A sample may be any bodily fluid or excreta (e.g., but not limited to, blood, urine, stool, saliva, tears, bile, or cerebrospinal fluid) that may or may not contain host or pathogen cells, cellular components, or nucleic acids.

[0131] The term "nucleic acid" as used herein refers to an oligonucleotide or polynucleotide of natural origin or synthesis, whether DNA or RNA or DNA-RNA hybrid, single-stranded or double-stranded, sense or antisense, capable of hybridizing to a complementary nucleic acid by Watson-Crick base pairing. The nucleic acids of the present invention may also contain nucleotide analogs (e.g., BrdU), modified or processed bases, and non-phosphodiester internucleoside linkages (e.g., peptide nucleic acid (PNA) or thiodiester linkages). In particular, nucleic acids may include, but are not limited to, DNA, cDNA, gDNA, ssDNA, dsDNA, RNA (including all RNA types such as miRNA, mtRNA, rRNA), or any combination thereof, including coding or non-coding regions.

[0132] By "probe", "primer" or "oligonucleotide" is meant a single-stranded nucleic acid molecule of a defined sequence that can base pair to a second nucleic acid molecule ("target") that contains a complementary sequence. The stability of the resulting hybrid depends on the length, GC content, and degree of base pairing that occurs. The degree of base pairing is affected by parameters such as the degree of complementarity between the probe and target molecules and the degree of stringency of the hybridization conditions. The degree of stringency of hybridization is affected by parameters such as temperature, salt concentration, and the concentration of organic molecules such as formamide, and is determined by methods known to those of skill in the art. Probes, primers, and oligonucleotides can be detectably labeled, either radioactively, fluorescently, or non-radioactively, by methods well known to those of skill in the art. dsDNA binding dyes can be used to detect dsDNA. It is understood that a "primer" is specifically configured to be extended by a polymerase, while a "probe" or an "oligonucleotide" may or may not be so configured. As probes, oligonucleotides can be used as part of many fluorescent PCR primer- and probe-based chemistries known in the art, including those that share the use of fluorescence quenching and / or fluorescence resonance energy transfer (FRET) structures, such as 5' nuclease probes (TaqMan® probes), dual hybridization probes (HybProbes®), or Eclipse® probes or molecular beacons, or Amplifluor® assays, such as Scorpions®, LUX® or QZyme® PCR primers (including those with natural or modified bases).

[0133] By "dsDNA binding dye" is meant a dye that fluoresces differently (usually more strongly) when bound to double-stranded DNA than when bound to single-stranded DNA or when free in solution. Reference is made to dsDNA binding dyes, but it is understood that any suitable dye can be used herein, with some non-limiting illustrative dyes described in U.S. Patent No. 7,387,887 (incorporated herein by reference). Other signal generating agents can be used to detect nucleic acid amplification and melting (illustratively enzymes, antibodies, etc. known in the art).

[0134] By "specifically hybridize" it is meant that a probe, primer, or oligonucleotide recognizes and physically interacts (i.e., base pairs) with a substantially complementary nucleic acid (e.g., a sample nucleic acid) under high stringency conditions and does not substantially base pair with other nucleic acids.

[0135] By "high stringency conditions" is meant approximately melting temperature (Tm)-5°C (i.e., 5 degrees below the Tm of the nucleic acid). Functionally, high stringency conditions are used to identify nucleic acid sequences having at least 80% sequence identity.

[0136] PCR is the amplification method used in the examples herein, but it is understood that any amplification method using primers can be suitable. Such suitable procedures include any type (single-step, two-step, or other) of polymerase chain reaction (PCR); strand displacement amplification (SDA); nucleic acid sequence-based amplification (NASBA); cascade rolling circle amplification (CRCA), loop-mediated isothermal DNA amplification (LAMP); isothermal chimeric primer nucleic acid amplification (ICAN); target-based helicase-dependent amplification (HDA); transcription-mediated amplification (TMA), next generation sequencing (NGS) technology, etc. Therefore, when the term PCR is used, it should be understood to include other alternative amplification methods, including amino acid quantification methods. For amplification methods without discontinuous cycles, reaction time may be used when measurements are made in cycles or Cp, and additional reaction time may be added if additional PCR cycles are added in the embodiments described herein. It is understood that protocols may need to be adjusted accordingly.

[0137] The term "crossing point" (Cp) as used herein (or cycle threshold (Ct), quantification cycle (Cq), or equivalent terms used in the art) refers to the number of cycles of PCR required to obtain a fluorescent signal above some threshold for a given PCR product (e.g., target or internal standard(s)) as determined experimentally. The cycle at which each reaction crosses the threshold depends on the amount of target (i.e., reaction template) present at the beginning of the PCR reaction. The threshold may typically be set at the point where the product fluorescent signal is detectable above background fluorescence, although other thresholds may be used. As an alternative to setting a somewhat arbitrary threshold, Cp may be determined by calculating the point for the reaction where the first, second, or nth derivative has its maximum value, thereby determining the cycle where the curvature of the amplification curve is maximum. An exemplary derivative method is taught in U.S. Patent No. 6,303,305, which is incorporated herein by reference in its entirety. Nevertheless, it usually does not matter much where or how the threshold is set, so long as the same threshold is used for all reactions being compared. Other points may be used as well, as known in the art, and any such points may be substituted for Cp, Ct, or Cq in any of the methods discussed herein.

[0138] By "sample processing controls" is meant pathogens, microorganisms, cells (living or not), nucleic acids, or any particles (natural or synthetic) that possess the ability to mimic a pathogen or a portion thereof, or nucleic acid, and its behavior in the workflow of a sample. Sample processing controls are often included in the device in known quantities to control some or all steps of the workflow that the sample follows, illustratively to ensure that the sample is properly lysed, that the nucleic acids of potentially infectious target pathogens are properly extracted and purified, and that the specific sequences of the target pathogens are properly amplified and detected.

[0139] Illustratively, the microorganism used as the sample processing control (illustratively Schizosaccharomyces pombe (S. pombe)) mimics as closely as possible the target microorganism to be detected and quantified. The sample processing control particles may reproduce the structure of the pathogen to be detected (e.g., membrane(s) and / or capsid and / or envelope), allowing the behavior of the pathogen and its target nucleic acid to be mimicked along the workflow. The goal of the sample processing control is to ensure that the yield of target lysis and nucleic acid extraction is similar to that of the sample processing control, and that the purified nucleic acid is properly processed to ensure optimal amplification / detection. For qualitative results, the pathogen may be reported as positive or negative, or inconclusive if the run control fails. To validate the run, the sample processing control may be one of several run controls, which should be positive (probably within a defined range), since some inhibitory conditions may reduce the yield of extraction, purification, or PCR amplification / detection. Sample processing controls can be used to monitor this type of inhibition, and yield reductions are similar between the sample processing controls and the target pathogen. With respect to qualitative results, such inhibition, even if undetected, can lead to false negative results. With respect to quantitative results, inhibition of one of the steps of the workflow can provide an underestimated quantification result. Thus, some illustrative embodiments of the present invention use at least one sample processing control (SPC) for at least two goals: 1) To control and verify the workflow: the classical role of SPC as described above, and 2) To aid in the quantification of targeted nucleic acid(s) in a test sample: a new role for SPC to also be used as a quantification standard.

[0140] By way of illustration, the SPC follows some or all of the treatments that the sample is subjected to. Thus, the SPC can be added before or during the step of lysing the sample. Sample treatment controls can be selected based on the type of target pathogen(s). For example, a bacteriophage such as PhiX 174 can be selected for virus-focused assays, where the bacteriophage is a good candidate to mimic the target virus, or a yeast such as S. pombe is for use in a wide range of bacterial and yeast quantification assays.

[0141] If a single pathogen is to be detected, two amplification assays, illustratively PCR assays (the target pathogen and a sample treatment control used as a quantification standard), can be designed to achieve identical or similar thermodynamic properties, allowing accurate quantification using a synthetic quantification standard (e.g., Example 5).

[0142] For quantification of multiple pathogens (i.e., multiplex amplification), it may be difficult to fit the amplification protocol (e.g., PCR design) of the sample processing control with the protocol of the amplification assay (e.g., PCR assay) for each pathogen to obtain identical thermodynamic properties, e.g., due to sequence variability and amplicon length. As a result, the PCR efficiency of different target pathogens may differ. For this purpose, a correction factor may be calculated for each pathogen to correct the quantification obtained using the quantification standard and the imported calibration curve.

[0143] Instead of synthetic quantification standards, calibration can be performed against known concentrations of known native microbial or other naturally occurring nucleic acid templates.

[0144] In another embodiment of the invention, reliable quantification of pathogens in any amplification system using at least two different (illustratively three or four different) sample processing controls is also possible, so long as these sample processing controls can be identified via known identification techniques, such as sequence-specific probes labeled with fluorescence, radioactivity, chemiluminescence, enzymes, or the like, as known in the art.

[0145] Although various examples herein refer to human targets and human pathogens, these examples are merely illustrative. The methods, kits, and devices described herein can be used to detect and sequence a wide variety of nucleic acid sequences from a wide variety of samples, including human, veterinary, industrial, and environmental.

[0146] Various embodiments disclosed herein illustratively use a self-contained nucleic acid analysis pouch for analyzing samples for the presence of various biological substances (illustratively antigens and nucleic acid sequences) in a single closed system. Such systems, including pouches and instruments for use with the pouches, are disclosed in further detail in U.S. Patent Nos. 8,394,608; and 8,895,295; and U.S. Patent Application No. 2014-0283945, which are incorporated herein by reference. However, such instruments and pouches are merely illustrative, and it is understood that the nucleic acid preparation and amplification reactions discussed herein can be performed in any of a variety of open or closed sample containers known in the art, including 96-well plates, plates of other configurations, arrays, carousels, and the like, using a variety of nucleic acid purification and amplification systems known in the art. The terms "sample wells", "amplification wells", "amplification containers", or the like, are used herein, and are meant to encompass wells, tubes, and various other reaction containers used in these amplification systems. Such an amplification system may include a single multiplex step in one amplification container, or multiple two-step individual reactions or low-order multiplex reactions in multiple individual reaction wells. In one embodiment, the pouch is used for assays for multiple pathogens. The pouch may include one or more blisters used as sample wells, illustratively in a closed system. Illustratively, various steps may be performed in the pouch, which may be disposable, including nucleic acid preparation, primary high-volume multiplex PCR, dilution of the primary amplification product, and secondary PCR, culminating with optional post-amplification analysis such as real-time detection or melting curve analysis. Furthermore, although various steps may be performed in the pouch of the present invention, it is understood that one or more steps may be omitted for a particular use and the structure of the pouch may be modified accordingly.

[0147] FIG. 1 shows an illustrative pouch 510 that may be used in or reconfigured for various embodiments. Pouch 510 is similar to FIG. 15 of U.S. Patent No. 8,895,295, and like items are numbered the same. Fitment 590 includes inlet channels 515a-515l, which may serve as reagent or waste reservoirs. Illustratively, reagents may be lyophilized within fitment 590 and rehydrated prior to use. Blisters 522, 544, 546, 548, 564, and 566 have respective channels 514, 538, 543, 552, 553, 562, and 565, and are similar to the like-numbered blisters of FIG. 15 of U.S. Patent No. 8,895,295. 1 is similar to that of U.S. Patent Application No. 8,895,295, however, the second-stage wells 582 of the high density array 581 are arranged in a somewhat different pattern. The more circular pattern of the high density array 581 of FIG. 1 eliminates corner wells and may result in more uniform filling of the second-stage wells 582. As shown, the high density array 581 includes 102 second-stage wells 582. The pouch 510 is suitable for use in a FilmArray® instrument (BioFire Diagnostics, LLC, Salt Lake City, UT). However, it is understood that the pouch embodiment is merely illustrative.

[0148] Although other containers can be used, illustratively, the pouch 510 is formed of two layers of flexible plastic film or other flexible material, such as polyester, polyethylene terephthalate (PET), polycarbonate, polypropylene, polymethyl methacrylate, and mixtures thereof, which can be made by any process known in the art, including extrusion, plasma deposition, and lamination. Aluminum laminated plastic or metal foil may also be used. Other barrier materials are known in the art that can be sealed together to form blisters and channels. If a plastic film is used, the layers can be bonded together illustratively by heat sealing. Illustratively, the material has low nucleic acid binding capacity.

[0149] For embodiments using fluorescence monitoring, plastic films with suitably low absorbance and autofluorescence at the operating wavelength are preferred. Such materials can be identified by testing different plastics, different plasticizers, and blend ratios, as well as different thicknesses of film. For plastics with aluminum or other foil lamination, the portion of the pouch that is read by the fluorescence detection device can remain foil-free. For example, if fluorescence is monitored in second-stage well 582 of second-stage reaction zone 580 of pouch 510, one or both layers of well 582 remain foil-free. In a PCR example, a film laminate of polyester (Mylar, DuPont, Wilmington DE) approximately 0.0048 inches (0.1219 mm) thick and polypropylene film 0.001 to 0.003 inches (0.025 to 0.076 mm) thick works well. Illustratively, pouch 510 is made from a transparent material capable of transmitting approximately 80% to 90% of incident light.

[0150] In illustrative embodiments, material is transferred between blisters by application of pressure (illustratively air pressure) to the blisters and channels. Thus, in embodiments using pressure, the pouch material is illustratively sufficiently flexible so that pressure has the desired effect. The term "flexible" is used herein to describe the physical properties of the pouch material. The term "flexible" is defined herein as being easily deformable by pressure levels as used herein without cracking, breaking, creasing, or the like. For example, thin plastic sheets, such as Saran® wrap and Ziploc® bags, and thin metal foils such as aluminum foil, are flexible. However, even in embodiments using air pressure, only certain areas of the blisters and channels need to be flexible. Furthermore, only one side of the blisters and channels need to be flexible, as long as the blisters and channels are easily deformable. The other area of ​​the pouch 510 may be made of a rigid material or may be reinforced with a rigid material.

[0151] Illustratively, a plastic film is used for the pouch 510. A sheet of metal (illustratively aluminum, or other suitable material) can be milled or otherwise cut to create a die with a pattern of raised surfaces. When fitted into a pneumatic press (illustratively A-5302-PDS, Janesville Tool Inc., Milton WI) controlled at an illustrative operating temperature of 195° C., the pneumatic press acts like a printing press, melting the sealing surface of the plastic film only where the die contacts the film. Various components, such as PCR primers (illustratively spotted and dried on the film), antigen-binding substrates, magnetic beads, and zirconium silicate beads, can be sealed inside the various blisters as the pouch 510 is formed. Reagents for sample processing can be spotted onto the film together or separately prior to sealing. In one embodiment, nucleotide tri-phosphates (NTPs) are spotted onto the film separately from the polymerase and primers to essentially eliminate the activity of the polymerase until the reaction is hydrated by the aqueous sample. If the aqueous sample is heated prior to hydration, it creates the conditions for true hot-start PCR, reducing or eliminating the need for expensive chemical hot-start components.

[0152] Pouch 510 may be used in a manner similar to that described in U.S. Patent No. 8,895,295. In one illustrative embodiment, 300 μl of a mixture containing the sample to be tested (100 μl) and lysis buffer (200 μl) is injected into an inlet (not shown) in fitment 590 adjacent to inlet channel 515a, drawing the sample mixture into inlet channel 515a. Water is also injected into a second inlet (not shown) in fitment 590 adjacent to inlet channel 515l and distributed through channels (not shown) provided in fitment 590, thereby hydrating up to eleven different reagents previously provided in dry form in inlet channels 515b-515l, respectively. These reagents may include, by way of example, lyophilized PCR reagents, DNA extraction reagents, wash solutions, immunoassay reagents, or other chemicals. Illustratively, the reagents are for nucleic acid extraction, first-stage multiplex PCR, dilution of the multiplex reaction, and preparation of second-stage PCR reagents, as well as control reactions. In the embodiment shown in FIG. 1, all that needs to be injected is the sample solution in one inlet and water in the other inlet. After injection, the two inlets can be sealed. For more information regarding various configurations of pouch 510 and fitment 590, see U.S. Patent No. 8,895,295, previously incorporated by reference.

[0153] After injection, the sample travels from injection channel 515a through channel 514 to the lysis blister 522. The lysis blister 522 is provided with beads or particles 534, e.g., ceramic beads, and configured for vortexing by impaction with a rotating blade or paddle provided within the FilmArray® instrument. Bead milling by shaking or vortexing the sample in the presence of lysing particles, such as zirconium silicate (ZS) beads 534, is an effective method of forming a lysate. Terms used herein, such as "lyse," "lysing," and "lysate," are not limited to rupturing cells, but are understood to include the disruption of non-cellular particles, such as viruses.

[0154] FIG. 4 shows a bead beating motor 819, which includes a blade 821 that can be mounted on a first surface 811 of the support member 802 of the device 800 shown in FIG. 2. The blade can extend through the slot 804 to contact the pouch 510. However, it is understood that the motor 819 can be mounted on other structures of the device 800. In one illustrative embodiment, the motor 819 is a Mabuchi RC-280SA-2865 DC Motor (Chiba, Japan) mounted on the support member 802. In one illustrative embodiment, the motor rotates at 5,000-25,000 rpm, more illustratively 10,000-20,000 rpm, and even more illustratively approximately 15,000-18,000 rpm. For the Mabuchi motor, it has been found that 7.2V provides sufficient rpm for lysis. However, it is understood that the actual speed may be somewhat slower when the blade 821 is impacting the pouch 510. Other voltages and speeds may be used for lysis, depending on the motor and paddles used. Optionally, a controlled small amount of air may be provided in the bladder 822 adjacent to the lysis blister 522. In some embodiments, partially filling the adjacent bladders with one or more small amounts of air has been found to help position and support the lysis blister during the lysis process. Alternatively, other structures, illustratively rigid or compliant gaskets or other retaining structures around the lysis blister 522, may be used to restrain the pouch 510 during lysis. It is also understood that the motor 819 is merely illustrative, and other devices may be used for milling, shaking, or vortexing the sample.

[0155] Once the cells are adequately lysed, the sample is moved through channel 538, blister 544, and channel 543 to blister 546 where the sample is mixed with a nucleic acid binding substance such as silica-coated magnetic beads 533. The mixture is incubated for a suitable time, illustratively about 10 seconds to 10 minutes. A retractable magnet located within the device adjacent to blister 546 captures the magnetic beads 533 from the solution and forms a pellet against the interior surface of blister 546. The liquid then moves out of blister 546 through blister 544 and back into blister 522, which now serves as a waste receptacle. One or more wash buffers from one or more of injection channels 515c-515e are provided to blister 546 via blister 544 and channel 543. Optionally, the magnet is retracted to wash the magnetic beads 533 by moving the beads back and forth from blisters 544 and 546 through channel 543. Once the magnetic beads 533 have been washed, activation of the magnet recaptures the magnetic beads 533 in blister 546 and the wash solution moves into blister 522. This process may be repeated as necessary to wash the lysis buffer and sample debris from the nucleic acid-bound magnetic beads 533.

[0156] After washing, the elution buffer stored in injection channel 515f is moved to blister 548 and the magnet is retracted. The solution is cycled between blisters 546 and 548 via channel 552 to disperse the pellet of magnetic beads 533 in blister 546 and allow the captured nucleic acids to dissociate from the beads and enter solution. The magnet is activated once more to capture the magnetic beads 533 in blister 546 and the eluted nucleic acid solution is moved to blister 548.

[0157] A first-stage PCR master mix from injection channel 515g is mixed with the nucleic acid sample in blister 548. Optionally, the mixture is mixed by forcing the mixture between 548 and 564 via channel 553. After several cycles of mixing, the solution is contained within blister 564, where a pellet of first-stage PCR primers is provided (at least one set of primers for each target) and the first-stage multiplex PCR is performed. If an RNA target is present, a reverse transcription (RT) step may be performed before or simultaneously with the first-stage multiplex PCR. Temperature cycling of the first-stage multiplex PCR in the FilmArray® instrument is illustratively performed for 15-30 cycles, although other levels of amplification may be preferred depending on the requirements of a particular application. The first-stage PCR master mix may be any of a variety of master mixes known in the art. In one illustrative example, the first-stage PCR master mix may be any of the chemistries disclosed in US2015 / 0118715 (incorporated herein by reference) for use in PCR protocols of 20 seconds or less per cycle.

[0158] After the first-stage PCR has proceeded for a desired number of cycles, the sample may be diluted, illustratively by transferring most of the sample back to blister 548, leaving only a small amount in blister 564, and adding second-stage PCR master mix from injection channel 515i. Alternatively, dilution buffer from 515i may be transferred to blister 566 and then mixed with the amplified sample in blister 564 by moving fluid back and forth between blisters 564 and 566. If desired, the dilution may be repeated several times with dilution buffer from injection channels 515j and 515k, or injection channel 515k may be reserved for sequencing or other post-PCR analysis, and then second-stage PCR master mix is ​​added to some or all of the diluted amplified sample from injection channel 515h. It will be appreciated that the level of dilution may be adjusted by varying the number of dilution steps, or by varying the percentage of sample that is discarded before mixing with a dilution buffer or second-stage PCR master mix that contains components for amplification (by way of illustration, polymerase, dNTPs, and a suitable buffer, although other components may be appropriate particularly for non-PCR amplification methods). If desired, this mixture of sample and second-stage PCR master mix may be pre-heated in blister 564 before moving to second-stage well 582 for second-stage amplification. Such pre-heating may eliminate the need for hot start components (antibodies, chemicals, or other) in the second-stage PCR mixture.

[0159] An illustrative second-stage PCR master mix is ​​incomplete, lacking primer pairs, with each of the 102 second-stage wells 582 being preloaded with a particular PCR primer pair (or sometimes multiple pairs of primers). If desired, the second-stage PCR master mix may be missing other reaction components, which may be preloaded into the second-stage wells 582 as well. Each primer pair may be similar or identical to the first-stage PCR primer pair, or may be nested within the first-stage primer pair. Transfer of the sample from blister 564 to second-stage wells 582 completes the PCR reaction mixture. Once the high density array 581 is filled, the individual second-stage reactions are sealed within their respective second-stage blisters by any number of means known in the art. An illustrative method for filling and sealing the high density array 581 without cross-contamination has been discussed in U.S. Patent No. 8,895,295, previously incorporated by reference. Illustratively, various reactions in wells 582 of high density array 581 are thermocycled simultaneously, illustratively using one or more Peltier elements, although other means for thermocycling are known in the art.

[0160] In certain embodiments, the second-stage PCR master mix includes the dsDNA binding dye LCGreen® Plus (BioFire Diagnostics, LLC) to generate a signal indicative of amplification. However, it is understood that this dye is merely illustrative and that other signals can be used, including other dsDNA binding dyes and fluorescent, radioactive, chemiluminescent, enzyme, or similar labeled probes known in the art. Alternatively, wells 582 of array 581 can be provided with an absence of signal, with the results reported through subsequent processing.

[0161] If air pressure is used to move material within pouch 510, in one embodiment, a "bladder" may be used. Bladder assembly 810 (portions of which are shown in FIGS. 2 and 3) comprises a bladder plate 824 housing a plurality of inflatable bladders 822, 844, 846, 848, 864, and 866 (each of which may illustratively be individually inflatable by a compressed gas source). Because bladder assembly 810 may be subjected to compressed gas and used multiple times, bladder assembly 810 may be made from a sturdier or thicker material than the pouches. Alternatively, bladders 822, 844, 846, 848, 864, and 866 may be formed from a series of plates secured together with gaskets, seals, valves, and pistons. Other arrangements are within the scope of the invention.

[0162] The success of the secondary PCR reaction depends on the template produced by the multiplex first stage reaction. Typically, PCR is performed with high purity DNA. Methods such as phenol extraction or commercially available DNA extraction kits provide high purity DNA. Samples processed through pouch 510 may need to be accommodated to compensate for lower purity preparations. PCR may be inhibited by components of the biological sample that are potential obstacles. By way of illustration, hot start PCR, higher concentrations of taq polymerase enzyme, adjustment of MgCl2 concentration, adjustment of primer concentration, and addition of adjuvants (e.g., DMSO, TMSO, or glycerol) may be used to compensate for lower nucleic acid purity. It is understood that purity issues may be more significant in first stage amplification and single stage PCR, but similar adjustments may be provided in second stage amplification as well.

[0163] When pouch 510 is placed in device 800, bladder assembly 810 is pressed against one side of pouch 510 so that as a particular bladder expands, the pressure forces liquid out of the corresponding blister in pouch 510. In addition to the bladders corresponding to the various blisters of pouch 510, bladder assembly 810 may have additional pneumatic actuators, such as bladders or pneumatically actuated pistons that correspond to the various channels of pouch 510. FIGS. 2 and 3 show illustrative multiple pistons or hard seals 838, 843, 852, 853, and 865 that correspond to channels 538, 543, 553, and 565 of pouch 510, as well as seals 871, 872, 873, 874 that minimize backflow into fitment 590. When activated, hard seals 838, 843, 852, 853, and 865 form pinch valves to pinch off and close the corresponding channels. To confine liquid within a particular blister of pouch 510, the hard seals are activated for the channels leading to and from the blister, such that the actuators act as pinch valves to pinch the channels closed. By way of illustration, to mix two volumes of liquid in different blisters, a pinch valve actuator sealing the connecting channel is activated and a pneumatic bladder over the blister is alternately pressurized to force liquid back and forth through the channel connecting the blisters and mix the liquid therein. Pinch valve actuators may be of various shapes and sizes and may be configured to pinch off more than one channel simultaneously. Although pneumatic actuators are discussed herein, it is understood that other methods of providing pressure to the pouch are contemplated, including a variety of electromechanical actuators, such as linear stepper motors, motor-driven cams, rigid paddles driven by pneumatic, hydraulic or electromagnetic forces, rollers, rocker arms, and in some cases, cocked springs.Furthermore, in addition to applying pressure perpendicular to the axis of the channel, there are various ways to reversibly or irreversibly close the channel. These include twisting a bag across the channel, heat sealing, rolling an actuator, and various physical valves sealed within the channel, such as butterfly and ball valves. Additionally, a small Peltier element or other temperature control element may be placed adjacent to the channel and set at a temperature sufficient to freeze the fluid, effectively forming a seal. It is also contemplated that while the design of FIG. 1 is adapted for automated equipment featuring actuator elements disposed on each of the blisters and channels, the actuators may remain stationary and may translate the pouch 510 in one or two dimensions, thereby allowing a small number of actuators to be used for some of the processing stations, including sample disruption, nucleic acid capture, first and second stage PCR, and other applications of the pouch 510, such as immunoassays and immunoPCR. Rollers acting against the channels and blisters may prove particularly useful in configurations in which the pouch 510 is translated between stations. Thus, although a pneumatic actuator is used in the embodiments disclosed herein, when the term "pneumatic actuator" is used herein it is understood that other actuators and other methods of providing pressure may be used depending on the configuration of the pouch and device.

[0164] Other prior art instruments teach PCR in a sealed flexible container. See, for example, U.S. Patent Nos. 6,645,758, 6,780,617, and 9,586,208, which are incorporated herein by reference. However, containing the cell lysate in a sealed PCR vessel can improve ease of use and safety, especially when the sample being tested may contain a biohazard. In the embodiment illustratively described herein, the waste from the cell lysis and all other steps remains in a sealed pouch. However, it is understood that the pouch contents may be removed for further testing.

[0165] 2 shows an illustrative device 800 that may be used with pouch 510. Device 800 includes a support member 802, which may form a wall of a casing or may be mounted within a casing. Device 800 may include a second support member (not shown), which may be movable relative to support member 802 to allow for insertion and retraction of pouch 510. Illustratively, a lid may cover pouch 510 once pouch 510 is inserted into device 800. In another embodiment, both support members may be fixed and pouch 510 is maintained in place by other mechanical means or air pressure.

[0166] In the illustrative example, heaters 886 and 888 are mounted on support member 802. However, it is understood that this arrangement is merely illustrative and that other arrangements are possible. Bladder plate 810 with bladders 822, 844, 846, 848, 864, 866, hard seals 838, 843, 852, 853, seals 871, 872, 873, 874 form bladder assembly 808 and illustratively may be mounted on a moveable support structure that may be moved toward pouch 510 such that a pneumatic actuator is positioned in contact with pouch 510. As pouch 510 is inserted into instrument 800 and movable support member moves toward support member 802, the various blisters of pouch 510 come into position adjacent the various bladders of bladder assembly 810 and the various seals of assembly 808 such that activation of a pneumatic actuator may force liquid out of one or more of the blisters of pouch 510 or form a pinch valve with one or more channels of pouch 510. The relationship between the blisters and channels of pouch 510 and the bladders and seals of assembly 808 is explained in more detail in FIG.

[0167] Each pneumatic actuator is connected to a compressed air source 895 via a valve 899. Although only a few hoses 878 are shown in FIG. 2, it is understood that each pneumatic fitting is connected to a compressed gas source 895 via a hose 878. The compressed gas source 895 may be a compressor, or alternatively, the compressed gas source 895 may be a compressed gas cylinder, such as a carbon dioxide cylinder. Compressed gas cylinders are particularly useful where portability is desired. Other compressed gas sources are within the scope of the present invention.

[0168] The assembly 808 is illustratively mounted on a moveable support member, although it will be appreciated that other configurations are possible.

[0169] Several other components of the device 810 are also connected to a compressed gas source 895. The magnet 850, which is attached to the second surface 814 of the support member 802, is deployed and retracted using gas from the compressed gas source 895 via a hose 878, illustratively, although other methods of moving the magnet 850 are known in the art. The magnet 850 resides in a recess 851 in the support member 802. It is understood that the recess 851 may be a passageway through the support member 802, such that the magnet 850 can contact the blister 546 of the pouch 510. However, depending on the material of the support member 802, it is understood that the recess 851 need not extend all the way through the support member 802, so long as the magnet 850 is close enough to provide a sufficient magnetic field at the blister 546 when the magnet 850 is deployed, and the magnet 850 does not significantly affect any magnetic beads 533 present in the blister 546 when the magnet 850 is retracted. Although reference is made to retracting the magnet 850, it is understood that an electromagnet may be used, which may be activated and deactivated by controlling the flow of electricity through the electromagnet. Thus, although this specification discusses retracting or retracting the magnet, it is understood that these terms are broad enough to incorporate other methods of removing the magnetic field. It is understood that the pneumatic connections may be pneumatic hoses or pneumatic air manifolds, thus reducing the number of hoses or valves required.

[0170] The various pneumatic pistons 868 of the pneumatic piston array 869 are also connected to a compressed gas source 895 via hoses 878. Although only two hoses 878 are shown connecting the pneumatic pistons 868 to the compressed gas source 895, it will be understood that each of the pneumatic pistons 868 is connected to a compressed gas source 895. Twelve pneumatic pistons 868 are shown.

[0171] A set of heating / cooling devices (illustratively Peltier heaters) are attached to the second side 814 of the support 802. A first-stage heater 886 is arranged to heat and cool the contents of the blister 564 for first-stage PCR. A second-stage heater 888 is arranged to heat and cool the contents of the second-stage blister 582 of the pouch 510 for second-stage PCR. However, it is understood that these heaters can be used for other heating purposes and that other heaters may be used as appropriate for a particular application. Other configurations are possible.

[0172] If fluorescence detection is desired, an optical array 890 may be provided. As shown in FIG. 2, the optical array 890 includes a light source 898 (illustratively a filtered LED light source, filtered white light, or laser illumination), and a camera 896. The camera 896 illustratively has a plurality of photodetectors, each corresponding to a second-stage well 582 in the pouch 510. Alternatively, the camera 896 may take an image including all of the second-stage wells 582, which may be split into separate fields corresponding to each of the second-stage wells 582. Depending on the configuration, the optical array 890 may be stationary, or the optical array 890 may be placed on a mover attached to one or more motors to move to obtain a signal from each individual second-stage well 582. It is understood that other arrangements are possible.

[0173] As shown, computer 894 controls valve 899 of compressed air source 895, and therefore all of the air pressure in instrument 800. Computer 894 also controls heaters 886 and 888, and optical array 890. Each of these components is electrically connected, illustratively via cable 891, although other physical or wireless connections are within the scope of the present invention. It is understood that computer 894 may be housed within instrument 800 or may be external to instrument 800. Additionally, computer 894 may include built-in circuit boards that control some or all of the components, may calculate amplification curves, melting curves, Cp, Ct, calibration curves, and other related data, and may also include an external computer, such as a desktop or laptop PC, for receiving and displaying data from the optical array. An interface may be provided, illustratively a keyboard interface with keys for inputting information and variables such as temperature, cycle time, etc. Illustratively, a display 892 is also provided. Display 892 may be, for example, an LED, LCD, or other such display. EXAMPLES

[0174] Example 1 - High-density PCR In one example, a standard commercially available immunofluorescence assay for common respiratory viruses is known to be able to detect seven viruses: adenovirus, PIV1, PIV2, PIV3, RSV, influenza A, and influenza B. A more complete panel would include assays for other viruses, including, illustratively, coronavirus, human metapneumovirus, rhinovirus, and non-HRV enterovirus. For highly variable viruses such as adenovirus or HRV, it is desirable to use multiple primers (illustratively, a set of four outer and four inner primers each) to target all branches of the virus' lineage. For other viruses, such as coronaviruses, there are four separate lineages (229E, NL63, OC43, HKU1) that do not change seasonally, but they are sufficiently divergent that separate primer sets are required. The FilmArray® Respiratory Panel (BioFire Diagnostics, LLC of Salt Lake City, UT) includes adenovirus, coronavirus HKU1, coronavirus NL63, coronavirus 229E, coronavirus OC43, human metapneumovirus, human rhinovirus / enterovirus, influenza A, influenza A / H1, influenza A / H3, influenza A / H1-2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, and respiratory syncytial virus. In addition to these viruses, the FilmArray® Respiratory Panel includes three bacteria: Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. The high density array 581 is capable of housing such a panel within a single pouch 510. Other panels are available for FilmArray®, each assaying for at least 20 pathogens.

[0175] An illustrative second-stage PCR master mix includes the dsDNA binding dye LCGreen® Plus to generate a signal indicative of amplification, however, it is understood that this dye is merely illustrative and that other signals can be used, including other dsDNA binding dyes and fluorescent, radioactive, chemiluminescent, enzyme, or similar labeled probes known in the art.

[0176] An illustrative FilmArray instrument is programmed to make a positive or negative call for each second-stage reaction based on the post-PCR melt. The melt curve must produce a melt peak (first derivative maximum or negative first derivative maximum) within a predefined temperature range for the call to be positive. It is understood that this method of calling each second-stage reaction is merely illustrative, and calls can be made using real-time amplification data or by other means known in the art.

[0177] Example 2 - Design of quantification standards for multiplex PCR In systems such as FilmArray, where a single multiplex PCR is performed in one reaction chamber, it is inconvenient to create a standard curve using 10-fold dilutions of a single reference template, since the individual levels cannot be easily distinguished. For example, if a single reference template is added to a single first-stage reaction chamber at concentrations of 10 copies, 100 copies, and 1000 copies, the final concentration of the reference template in that chamber will be 1110 copies, and there will be no other labels present, making it impossible to distinguish the individual dilutions. Furthermore, in two-step multiplex PCR systems, a standard curve created only with a nested second-stage PCR may be of limited value for quantification, since the amplification reaction of the single-plex standard template may not accurately reflect all of the upstream operations that the sample undergoes, or may not be amplified with the same efficiency, and therefore may not reflect the entire process.

[0178] In this illustrative example, different nucleic acid templates (illustratively different in sequence and / or length), illustratively synthetic quantification standards, are used to represent different levels of the dilution series. In one illustrative embodiment, the assays for all synthetic quantification standards have similar amplification efficiencies and produce the same or similar Cp values ​​at each given dilution point in a multiplex setting. Illustratively, all target assays are optimized for the same performance characteristics (including efficiency), but compensation can be applied to adjust for assay-specific variations in efficiency.

[0179] In one illustrative example, the size of the outer amplicon and inner amplicon for the quantification standard may be representative of the size of the amplicon for the quantitative target assay. Also, the sequence or GC content may be identical or similar between the priming regions. Illustratively, the sequence may be identical except for at least one inner priming region (which should be sufficiently different to avoid cross-reactivity between the inner assays). If only the inner primer binding regions differ in sequence, the same PCR1 primer may be used to amplify all quantification standards, thus minimizing potential differences in the performance of the PCR1 assay. Furthermore, if a label is used, the sequence may be identical, and if a label is not used, even slight differences in sequence may be provided for detection (in a second-stage singleplex reaction as an example). However, it is understood that these parameters are merely illustrative and there may be other means for detecting and controlling amplification efficiency. The quantification standard present in the multiplex reaction may be Mg 2+ It is understood that the PCR reaction should be designed to match reaction parameters such as primer concentration, Tm, and cycling conditions. It is also understood that it is desirable to minimize non-specific amplification of synthetic templates in multiplex PCR reactions.

[0180] FIG. 5 shows the Cp versus concentration of four prospective internal quantification standards. In this illustrative embodiment, the internal quantification standard has a synthetic sequence. In this illustrative example, for the second stage inner reaction, the four quantification standards all share one common primer and each has one unique specific primer. They were also designed to share both outer primers for the first stage PCR. Thus, each of the second stage wells used to detect the quantification standards is spotted with a common primer and a primer for that quantification standard, so that only one quantification standard should amplify in each such well. However, it is understood that this is merely an illustrative example and other configurations are possible. Syn2, Syn3, and Syn4 each have similar amplification efficiency and were selected for further testing. Syn1 behaved differently and was omitted from further testing. Therefore, in one embodiment, it is desirable to have multiple quantification standards with similar amplification efficiency.

[0181] In this illustrative example, amplification was detected using the dsDNA binding dye LCGreen Plus, however this is merely illustrative and other dsDNA binding dyes, probes, signals, or other methods of detecting amplification are within the scope of the invention.

[0182] It is understood that there are various methods to design quantification standards with similar amplification efficiency. In one embodiment, the quantification standards have the same sequence between the inner primers, and only the binding sequence of the inner primers is different. In another embodiment, the quantification standards are all substantially the same length and substantially the same GC content. In yet another embodiment, the sequences are different in length but also in GC content to compensate. Other methods to design nucleic acids with similar amplification efficiency are known in the art.

[0183] In one embodiment, illustratively when quantification standards are used in a two-step nested multiplex PCR reaction, the quantification standards may all use the same outer primers in the first stage PCR reaction, potentially sharing the same region surrounding the primers to avoid differences due to the shape of secondary structures. The quantification standards may be differentiated by using different inner primers in the individual second stage PCR reactions, with each calibrator having a unique inner primer pair, or sharing one inner primer and having one unique inner primer, as described above. Such an embodiment is advantageous in that each of the quantification standards may bind to its first stage primer with the same kinetics, minimizing the complexity of the first stage multiplex PCR reaction.

[0184] Although reference is made to two-step PCR, the same principle can be used in single-step multiplex PCR. In this case, the quantification standard may have different forward or reverse primers, or the same forward and reverse primers (each with a specific fluorescent probe or other identifiable label, such as chemiluminescence, bioluminescence, radiofluorescence, electroluminescence, electrochemiluminescence, mechanoluminescence, crystalloluminescence, thermoluminescence, sonoluminescence, phosphorescence and other forms of photoluminescence, enzymes, radioactivity, etc., as illustratively contemplated herein). Applications are limited only by the number of detection channels available in any system or other methods for distinguishing labels known in the art. Some labels may require post-amplification processing. Furthermore, it is understood that labeled quantification standards can be used in two-step PCR, where the same or different primer sequences may be used, and the labels are used to detect in the second-stage PCR. In such an embodiment, the labeled quantification standards may be diverse in the second-stage PCR and are distinguished by the labels.

[0185] Although synthetic quantification standards are used in this example, it is understood that the sequences used for the quantification standards may be naturally occurring. For example, if yeast is used as the SPC, yeast sequences may be used for one or more of the quantification standard sequences. For the fission yeast Schizosaccharomyces pombe, Tf2-type retrotransposons / transposons are present in 13 copies, while ribosomal RNA genes are repeated 47 times. In another example, gene sequences present in different copy numbers may be used. By way of illustration, fungal pathogens have 50-200 copies of ribosomal RNA genes per nuclear genome. These pathogens also have transposons that vary from 5-20 copies per genome. Bacterial pathogens have 1-15 copies per genome, but the majority have more than 5 copies. Other naturally occurring or synthetic templates (e.g., bacteriophages and synthetic particles that can mimic membrane and / or capsid and / or envelope structures for viruses) may be used. Additionally, although three quantification standards are used in many of the examples herein, it is understood that only two quantification standards are necessary to define a linear calibration curve, and that in embodiments where a wide range of target concentrations is expected or where a non-linear calibration curve is expected, more quantification standards may be desirable. Illustratively, the number of quantification standards may be selected based on the dynamic range of the system and the requirements of the assay.

[0186] Alternatively, as shown in Example 5, it is possible to use only one quantification standard in each experimental run (see Sample Processing Controls (SPC) discussed in Example 5) and rely on imported calibration curves for quantification previously created in the range of quantification standards, by way of example, with at least three quantification standards (named QS in Example 5) that may be included within the software for this analysis.

[0187] Example 3 - Multiple Calibration Figure 6A is similar to Figure 5, but shows data from only three selected calibrator sequences. Figure 6A demonstrates linearity and nearly identical amplification efficiency for three illustrative quantification standards. Figure 6B shows a composite calibration curve made from a combination of three points for each of the three quantification standards over a total of five dilutions.

[0188] Now that an illustrative calibration plot has been generated, calibration curves using assay-specific reference templates can be generated for each target assay. Figure 7 compares an external calibration curve generated using a fully quantified synthetic reference template for Acinetobacter baumannii to a hybrid internal calibration curve generated using quantification standards. Here, three "Syn" templates are premixed before being added to the reaction tubes; Syn4 is 10 per reaction; 3 Syn2 is added in 10 copies. 4 Syn3 is added in 10 copies. 5 The Cp values ​​from these templates were used to generate an internal hybridization standard curve for each reaction. An external standard curve was generated using a synthetic reference template, the A. baumannii reference template, tested at the same concentration as the "Syn" template. The hybridization internal standard curve and the A. baumannii standard curve are very similar. The similar slopes indicate similar efficiencies. It is expected that the internal standard curve can be used to predict the unknown initial concentration of the A. baumannii sample. However, since the y-intercept is shifted between the two curves, quantification of A. baumannii may benefit from a correction factor when using this internal standard curve.

[0189] Thus, the concentration of the target organism can be calculated using the internal calibration curve of the hybrid. Note that the internal standards are each at a different known concentration and are amplified in the same step as the target organism. The method illustratively uses cycle threshold (Ct) values ​​(or Cp values ​​or other similar methods), which are the number of PCR cycles required to obtain a fluorescent signal higher than background fluorescence for the target and internal standard, as determined experimentally. Other points can be used as well, for example, using first, second, or nth derivatives, as taught illustratively in U.S. Patent No. 6,303,305 (incorporated herein by reference in its entirety). Other points can be used as well, as known in the art, and any such points can be substituted for Cp or Ct in any of the methods discussed herein. Illustratively, in a two-step multiplex system, the Cp value is determined in a nested second-step reaction. However, it is understood that in other embodiments, Cp can be determined as appropriate for the amplification system. For example, Cp can be determined by using oligonucleotide probes in a single multiplex reaction or in a subsequent second-stage reaction, each of which is specific for a quantification standard sequence and has distinguishable fluorescent signals.

[0190] In an illustrative embodiment where a single internal standard is used, the concentration of the target organism is determined by the Cp of the target organism (Cp t ), the concentration of the internal standard and Cp (concentration s , Cp s ), as well as the efficiency of the target organism ( t ) can be calculated according to the following formula: concentration t =concentration s *efficiency t (Cps-Cpt) [Equation 1], where the subscripts s and t represent the internal quantification standard and the target organism, respectively. efficiency t = 1 + Efficiency as a percentage / 100 [Equation 2] It is.

[0191] For example, the variable efficiency for a target with 100% amplification at each PCR cycle = 2. Note that the efficiency is predefined and assumed to be constant across the dynamic range. As mentioned above, the efficiencies of the internal calibrators should all be similar (illustratively within 1%, 2%, 5%, or 10% of each other). Similarly, the efficiency of the target should be similar to the efficiency of the calibrators, respectively (illustratively within 2%, 5%, 10%, or 12% of the calibrators). It is understood that for accurate quantification, efficiencies within a narrower range (illustratively within 1%, 2%, or 5%) are desirable. However, for semi-quantitative or "binning" results (see below), a larger variation in efficiency may be tolerated.

[0192] When more than one quantification standard is used, as illustrated in Figures 6A-6B, by way of example, the (Cp,log 10 A standard quantification curve can be generated using a least squares regression line fitted to the (concentration) data. Illustratively, the regression fit is the following equation: log 10 (Concentration)=(Cp-b) / a [Equation 3], where b is the intercept and log 10 where a represents the value of Cp when (concentration)=0, and a is the slope, which represents the degree to which Cp changes with a single unit change in template concentration (a function of efficiency). Given a calculated Cp value for an unknown target, this formula scales the target concentration with Log 10The quantification standard curves are given in units. Other algorithms or equations may be applied as necessary to improve the accuracy and precision of quantification. These may include adjustments required for platform-specific, matrix-specific, or assay-specific biases in extraction and / or amplification. They may also include algorithms that can account for differences in assay efficiency at separate steps of any multi-step amplification process. In some embodiments, the quantification standard curves may be non-linear or linear only within a certain dynamic range. By way of illustration, a sigmoidal dose-response curve may be used where there is a variable slope of concentration dependence. Other non-linear curves are within the scope of the invention.

[0193] The above method can be used for target organisms with unknown concentrations based on the regression equation for the calibration curve created using the observed Cp values ​​for the target and the internal quantification standard. Ideally, all targets quantified using this technique should have an assay with the same or similar PCR efficiency as the internal quantification standard assay. However, there may be some variation in the slope or intercept of the target assay standard curve. Given that the target assay may have different amplification characteristics than the internal standard, assay-specific correction factors can be used to adjust for systematic assay-specific biases to improve the accuracy of the calculated concentration of the unknown target. By way of example, if a linear quantification curve is used, a can be corrected by a correction factor that represents a different assay-specific efficiency (changing the slope), or b can be corrected due to the absence of optimal PCR conditions for a particular target (delaying the Cp of the target). Both corrections may be used if appropriate. In another example, by way of example, if nested PCR is used, the difference in b observed in PCR2 may be the result of the overall performance of the PCR1 assay due to variations in PCR1 efficiency. In this case, the correction factor may be calculated as a function of the Cp value or may be a constant depending on the desired quantification accuracy.

[0194] For example, a set of controlled experiments may be performed with known target organism concentrations. If multiple replicates are used at a single concentration, an assay-specific correction factor may be calculated as the average difference between the known and calculated concentrations, expressed as Log 10 It can be calculated in units. Illustratively, to obtain the corrected log concentration of the target organism, an assay-specific correction factor can be added to the log concentration of the target organism (calculated above by the method of internal quantification standard). Illustratively, each target sequence in a multiplex assay has its own correction (or no correction at all if it is very similar to the composite standard curve).

[0195] An experiment was set up to compare the quantification of the target organism calculated by the assay-specific calibration curve with that calculated by the internal calibration curve of the hybridization. In this experiment, a known amount of A. baumannii genomic nucleic acid in 10-fold serial dilutions was multiplexed with the internal quantification standard in a benchtop reaction. An external assay-specific calibration curve was also set up as described above with respect to FIG. 7. FIG. 8A shows the results using the external calibration curve specific for A. baumannii and the hybridization calibration curve from the quantification standard. When the hybridization calibration curve is used without correction, there is a clear systematic overquantification (about 0.5 log copy units) of the target organism (A. baumannii), but when a correction of 0.5 log copy units is applied, the corrected assay-specific calibration curve gives a fairly accurate estimate of the A. baumannii titer in the sample. FIG. 8B shows how this systematic bias in quantification can be corrected by applying the average assay-specific correction factor created as described above to the amount calculated by the internal calibration curve method. Similar corrections may be made for each assay in a multiplex reaction.

[0196] In many embodiments, absolute quantification is not necessary, and semi-quantitative results may be sufficient. Results may be reported as absolute concentrations (with or without systematic error (as an example, 95% prediction interval)) or may be binned into one of several ranges (as an example, reporting "high", "medium" or "low" concentrations, each covering one or more orders of magnitude). It is understood that the number of bins may be changed as appropriate for a particular assay, and any number of bins may be used. Also, the binning range (order of magnitude or other scale) for semi-quantitative results may be adjusted as appropriate for a particular example.

[0197] Example 4 - Methods for normalizing and quantifying sequencing data In addition to or instead of the assay methods and systems described in Examples 1-3, next generation sequencing (NGS) methods. NGS can be used, for example, for the detection, identification and quantification of potentially pathogenic organisms in a sample. In another example, NGS can be used as a so-called "comparator" to confirm the performance of another assay, such as one of the assay methods and systems described in Examples 1-3. In a particular example, NGS includes PCR followed by next generation sequencing.

[0198] Modern sequencing equipment (e.g., NGS equipment) can produce large amounts of data that can be computationally cumbersome to analyze. Additionally, the sequencing process (e.g., sample type, sample preparation, amplification, and sequencing) and the resulting data can contain multiple confounding factors that can make the data difficult to analyze and / or compare across experiments, labs, etc. For example, samples may not be uniformly prepared for sequencing due to human error (i.e., random error) and systematic error. In another example, samples may not be sequenced uniformly due to nucleic acids from multiple organisms or multiple length ranges being present at various concentrations. For example, saliva is a particularly abundant sample type, with approximately 0-10 13 The bioload can range from about 10 per ml to about 10 per ml.3 ~10 9 Organisms are quite typical. Other clinical samples such as feces or blood culture medium may have similar organism loads. Similarly, clinical samples may contain large amounts of host DNA (e.g., human DNA). In addition, sequencing libraries from multiple samples may be pooled together before sequencing, thereby shortening the time required for sequencing because multiple samples are analyzed simultaneously, but may dramatically increase the amount of data collected in a single sequencing run. Furthermore, individual samples in a sample pool may not be uniformly prepared due to the factors mentioned above. Data from individual pooled samples are typically separated within the dataset for individual alignment and analysis.

[0199] To address these and other similar issues, it has been found that a known amount of reference DNA sequence (herein referred to as quantification standard material (QSM) or internal quantification standard) can be added to the sample intended for sequencing prior to sample preparation (e.g., prior to nucleic acid extraction and amplification) and prior to sequencing; thus, the internal quantification standard is retained throughout all sample processing and sequencing steps. Because the internal quantification standard is added at the beginning of sample processing, the number of sequencing reads for the sequenced standard (i.e., the number of molecules of the sequenced standard) is not limited, but accurately reflects all of the manipulations and systematic losses that the sample may undergo through steps such as sample preparation, amplification, nucleic acid recovery, purification, and sequencing. Similarly, because the internal quantification standard is added separately to each sample prior to extraction, library preparation, and pooling, the standard added to each sample can accurately reflect all of the processing steps that each sample is subjected to. In one embodiment, the internal quantification standard added separately to each sample in a sample pool is identical. In one embodiment, each amplified sequence within a pool has a unique sample-specific identification sequence (e.g., a DNA barcode) that allows nucleic acids from each sample to be tracked, separated, and normalized to each sample.

[0200] The internal quantification standard (i.e., reference DNA sequence) can be essentially any natural or synthetic nucleic acid sequence, so long as it is distinguishable from other nucleic acids in the sample to be sequenced. For example, the internal quantification standard can be a naturally occurring or modified plasmid, a naturally occurring or synthetic linear DNA fragment, or the like. Because the efficiency of sample preparation, DNA amplification, purification, and sequencing are all affected by the size of DNA, the internal quantification standard should be in a close size range to the unknown sequence in the sample. For example, if the fragment of DNA to be sequenced has a size in the range of 200-500 base pairs, the internal quantification standard should also have a size in the range of 200-500 base pairs. Furthermore, the composition (e.g., relative GC content) of the internal quantification standard should also be relatively similar to the composition of the DNA to be sequenced.

[0201] In one embodiment, a known amount of internal quantification standard may be added to the sample to be sequenced. If multiple samples are to be sequenced, the internal quantification standard may be added separately to each sample. In one embodiment, the known amount of internal quantification standard is determined based on the assay. For example, the amount of internal quantification standard sufficient for the assay may depend on factors such as, but not limited to, the desired resolution of the assay, the efficiency of nucleic acid extraction, the concentration range of the nucleic acid to be sequenced, the prevalence of genetic mutations to be detected, or the desired sequencing read depth. In one embodiment, the known amount of internal quantification standard may be added in an amount within the linear range of the assay, i.e., for example, above the limit of detection (LOD) and below the maximum concentration expected for the assay. For example, in the particular example discussed herein, the linear range of DNA copies / ml that can be sequenced and differentiated in a sequencing assay is about 10 2 ~about 10 7 ~10 8 copies / ml, in which case the internal quantification standard is approximately 10 4 ~10 6The amount of internal quantification standard added may be in copies / ml. As explained in more detail below, the amount of internal quantification standard added and the sequencing read depth are related to the LOD of the assay.

[0202] To sequence the nucleic acids in a sample, RNA or DNA is extracted from the sample tissue / cells and fragmented. RNA is converted to cDNA by reverse transcription. The step of preparing the sample with an internal quantification standard for sequencing includes the creation of DNA fragments, which are converted into a "library" by annealing or ligating to sequencing adaptors that contain specific sequences designed to interact with the sequencing platform and sample-specific identification sequences (e.g., DNA "barcodes") that can be used to identify sequencing data derived from a particular sample. When two or more samples are pooled and sequenced in parallel, each sample has its own sample-specific identification sequence or "barcode" that can be used to distinguish data derived from each sample. This procedure is primarily compatible with Illumina sequencing technology. However, it should be noted that almost all principles discussed herein can be applied with minimal modifications to NGS platforms developed by Life Technologies, Roche, Pacific Biosciences, and others.

[0203] The next step involves sequencing the DNA. The exact method of sequencing depends on the sequencing platform, but all modern massively parallel sequencing technologies are somewhat similar and produce similar data.

[0204] After sequencing, the reads derived from the internal quantification standard may be counted in each sample to normalize the NGS dataset for each sample. As a first check, there should be a linear relationship between the amount of internal quantification standard added to the sample and the number of sequencing reads observed for the internal quantification standard. Additionally, the minimum number of internal quantification standard sequencing reads ("F") should be recorded. Normalization (1) applies a data pass / fail criterion to the sequencing dataset based on the presence of a minimum number of sequencing reads for the internal quantification standard for the sample, and (2) ensures that substantially the same limit of detection (LOD) is applied to all unknown nucleic acids in the sequencing assay. If samples are pooled, normalization ensures that all samples are read to sufficient depth, ensures that all samples maintain the same number of QSM read pairs, and ensures that substantially the same limit of detection (LOD) is applied to all unknown nucleic acids in all samples in the sequencing assay.

[0205] Assuming a linear relationship exists and "F" internal quantification standard / QSM reads are recorded, the sequencing data can be processed according to Equation 4 to maintain a normalized number of sequencing reads: NORM = number of sequencing reads * (F / number of observed sequencing reads derived from internal quantification standard) [Equation 4] "F" is a user-set minimum expected number of fixed, assay-specific internal quantification standard sequencing reads. For example, "F" is a value of the number of sequencing reads that is set to ensure sufficient sequencing read depth to detect nucleic acids at or near the limit of detection (LOD) of the sequencing assay.

[0206] NORM may represent a subset of the sequencing data, the number of sequencing reads, which are stored for further analysis and quantification. As can be seen from Equation 4, if the observed number of sequencing reads derived from the internal quantification standard is equal to "F", the amount in parentheses will be "1", so that NORM is equal to the number of sequencing reads recorded. On the other hand, if the number of sequencing reads of the internal quantification standard in the data set is greater than "F", the amount in parentheses will be <1, and the NORM equation will downscale the data and account for the over reads to ensure that the same LOD is applied across all samples. If the number of sequencing reads of the internal quantification standard in the data set is less than "F", the data from that sample may be rejected, and the sample may be subjected to further sequencing until "F" internal quantification standard reads are recorded.

[0207] The number of QSM reads to maintain, "F", is a parameter that is selected during the assay run and is related to the read depth and limit of detection (LOD) of the assay. This effect is illustrated in Table 1 below. JPEG0007590954000001.jpg117166

[0208] For example, if the internal quantification standard is present in a sample at 5 x 10 5 If added at a concentration of copies / ml, a different number of QSM reads need to be recorded to ensure that all unknown nucleic acids above the LOD are fully sequenced and detected. This is called the sequencing read depth. For example, if an internal quantification standard / QSM is added to a sample at 5 × 10 5 If "F" is 500, the LOD for the assay for detection of an unknown nucleic acid is 10 3 copies / ml or more (typically 10 3 ~10 4 copies / ml); if "F" is 5000, the LOD of the assay is 10 2copies / ml or more (typically 10 2 ~10 3 copies / ml range); or, if "F" is 50,000, the LOD of the assay is 10 copies / ml or greater (typically 10-10 2 copies / ml). Thus, it can be seen that the LOD of an assay can be lowered by increasing the read depth of the assay (i.e., increasing "F"). However, arbitrarily setting "F" high is pointless since it also increases the sequencing burden. For example, if the LOD of an assay is greater than 10 copies / ml ("F" = 50,000) and the most prevalent species is greater than 10 9 If present at 10 copies / ml (which is not uncommon), 9 The most prevalent target, expressed in copies / ml, was 10 1 ~10 2 To achieve only 1-10 (e.g., 4) reads for a target present in the copies / ml range, one would sequence 100 million times, which would be impractical.

[0209] In the examples described herein, "F" is typically set to 5000 QSM leads because this is 3 ~10 7 This is because it is sufficient to reproducibly ensure detection of nucleic acids present in the range of copies / ml or more. For more stringent or less stringent assays, "F" may be set differently. Thus, in one embodiment, the sequencing read depth (i.e., "F") may be as low as 100 to 1000 QSM reads, or in the range of about 1000 internal quantification standard sequencing reads to about 100,000 internal quantification standard sequencing reads, preferably about 2000 internal quantification standard sequencing reads to about 75,000 internal quantification standard sequencing reads, more preferably about 5000 internal quantification standard sequencing reads to about 50,000 internal quantification standard sequencing reads, or most preferably at least 5000 internal quantification standard sequencing reads.

[0210] The power of the internal standard and the value of "F" are further explained with reference to FIG. 9. FIG. 9 illustrates a hypothetical example of a sequencing data set for three samples (A, B, and C). Each sample was spiked with 10 QSM copies, and each sample contained unknown amounts of nucleic acids X and Y. For each sample, 20,000 sequencing reads were collected. In sample A, the sample did not contain X or Y explicitly, and all 20,000 reads were attributable to QSM. Of the 20,000 reads in sample B, 18182 reads were attributable to QSM, 1818 reads were attributable to X, and no reads were attributable to Y. Sample C illustrates a different case. Of the 20,000 reads in sample C, 20 reads were attributable to QSM, 2 reads were attributable to X, and 19978 reads were attributable to Y. From the initial read attributes, it can be seen that sample C has a very high concentration of Y and a relatively low concentration of X. Nevertheless, sample C has fewer than 5000 QSM reads, and therefore the sample must be subjected to further sequencing until at least 5000 QSM reads are recorded. However, in the case of sample C, this means that Y is sequenced nearly 5 million times to achieve the minimum QSM coverage. Although this may seem cumbersome compared to the industry standard (which may set a minimum total read value for each sample (e.g., 20,000 reads or 200,000 reads or 2 million reads), and assume that all detectable nucleic acids are sequenced when this total is achieved), the method described herein ensures that the same read depth is achieved across all three samples A, B, and C, and ensures that sequencing has an equal chance of detecting rare nucleic acids in each sample. In the case of sample C, even when 2 million total reads were recorded, the sample was still "under read", which seems like it should be a sufficient number, but in this case 2 million reads still resulted in an insufficient number of QSM reads and the sample was under read with respect to the LOD of the assay.However, when sequencing actual clinical specimens with unknown amounts of nucleic acids, it may be impossible to know at what point sufficient read depth is achieved without an internal quantification standard. That is, unknown nucleic acids in the sample (e.g., X and Y in sample C) are not given an equal chance to be detected at LOD until there are sufficient QSM reads. Also, even with 2 million or 200,000 reads, it should be possible to detect X and Y, but without QSM it may be impossible to quantify X and Y, and it may be impossible to determine when sufficient read depth is achieved to detect all rare nucleic acids in the sample. Since more than 5000 reads were attributable to QSM in samples A and B, the requirement of "F" is met and samples A and B pass. Thus, the hypothetical case above shows that the internal quantification standard discussed herein is a reliable tool.

[0211] Further referring to FIG. 9, "F" is a fixed, assay-set, minimum expected number of internal quantification standard sequencing reads, and NORM [Equation 4] may result in a subset of sequencing reads being saved for further analysis and quantification. If "F" is the same as the observed number of sequencing reads derived from the internal quantification standard, NORM is equal to the number of recorded sequencing reads. In contrast, if a sample is "over read" (e.g., samples A and B in FIG. 9), NORM downscales the data to account for the over reading, ensuring that the same LOD is applied across all samples. For example, in sample A, there were 20,000 reads due to QSM; this sample is "over read" with respect to QSM, and NORM=20,000*(5000 / 20,000)=5000. That is, only one-quarter of the data in sample A is saved for further analysis. Similarly, for sample B, NORM = 20,000 * (5000 / 18182) = 5500. Sample C is "under-read" with respect to QSM and is therefore not normalized or further analyzed, but instead is subjected to further sequencing.

[0212] Now referring to Figures 10 and 11, raw read counts and QSM reads for a set of clinical samples are described. The samples described in Figures 10 and 11 are pooled for sequencing after QSM spiked; analysis proceeds with sequencing library preparation and sequencing data collection. Figures 10 and 11 describe 32 samples pooled for sequencing. Each sample is spiked with its own QSM, and each sample has its own unique tracking sequence (e.g., DNA barcode) that anneals, ligates or otherwise associates with all unknown nucleic acids in the sample and each sample's QSM during sample preparation. These unique tracking sequences are associated with all nucleic acids in each different sample and are retained throughout all steps of sample preparation and sequencing, and the unique tracking sequences allow data derived from the nucleic acids in each sample to be separated from the pooled sequencing data set for data analysis. In the example described in Figures 10 and 11, 32 samples are pooled and sequenced together, but more or fewer samples may be pooled in practice. For example, 1000 or more samples may be pooled for one sequencing run, assuming that sufficiently discriminatory barcodes and sufficient read depth are present for all samples. In one embodiment, 2-1000 samples may be pooled after sample preparation and before sequencing, preferably 2-500 samples may be pooled after sample preparation and before sequencing, more preferably 2-100 samples may be pooled after sample preparation and before sequencing, more preferably 2-50 samples may be pooled after sample preparation and before sequencing, or most preferably 2-32 samples may be pooled after sample preparation and before sequencing.

[0213] In Figures 10 and 11, 32 samples were pooled and sequenced simultaneously. The QSM added to each sample and the unique tracking sequence associated with each sample allows the sequences from each individual sample to be separated and analyzed separately. In Figure 10, it is interesting to note the wide range of sequencing reads associated with each sample. For example, sample 15 accounts for more than one-third of all sequencing reads in the data set, while some samples (e.g., sample 13) have less than one-tenth the reads of sample 15. Figure 11 shows the QSM reads. Three samples, 12, 27, and 29, had fewer than 5000 QSM reads and failed the initial QSM check. Sample 23 had just enough QSM reads to pass, while samples 6, 9, 10, and 14, etc., were substantially over-read with respect to QSM. Interestingly, sample 15 had a fairly high raw read count, but its QSM read levels were not as high. Nevertheless, due to the normalization described herein, all passing samples are given equal weight. That is, sample 23, etc., with only about 5000 QSM reads, will not be significantly trimmed in the normalization process, but data from samples 6, 9, 10, and 14, etc., may be trimmed, since the abundance of QSM reads in these samples indicates that data from these samples make up a significantly larger proportion of the data set. Thus, it can be seen that the normalization process described herein ensures that all samples are given equal weight and the same LOD is applied to all samples.

[0214] In one embodiment, the unknown nucleic acid reads and the internal quantification standard reads can each be separately normalized by the same ratio ALPHA according to Equation 5: ALPHA=F / number of observed sequencing reads derived from the internal quantification standard [Equation 5]

[0215] This is illustrated pictorially in FIG. 12. Data for a sample includes QSM reads and non-QSM reads. When these are normalized together (and down-read together), the final number of QSM reads in the normalized dataset may not be exactly "F" (e.g., 5000) - instead, for example, there may be about 4970-5030 QSM reads in the binned dataset. This is because the sampling process used to create the NORM dataset was randomized, and the underlying probability model for random sampling events predicts that the random seed will not pull exactly "F" QSM reads from the entire dataset when creating the NORM dataset. Alternatively, the QSM and non-QSM data may be separated and binned, and normalized using ALPHA, thereby yielding exactly "F" QSM reads (e.g., 5000) in the QSM bin and the appropriate number of reads in the non-QSM bin. Specifically, pseudorandom stratified subsampling may be used to maintain the appropriate number of reads derived from QSM in each sample's dataset. This normalization ensures that the sequencing depth and LOD are uniform across samples, reducing the computational burden of subsequent analysis steps. To perform QSM alignment and normalization, QSM reads are separated from non-QSM reads by alignment according to well-established procedures known in the art. This separates the read pairs into a set that originates from QSM and a set that does not originate from QSM. The count of QSM read pairs is used to calculate a subsampling fraction for each sample, where the subsampling fraction is given by Equation 5. The subsampling fraction and the count of non-QSM read pairs are used to calculate the number of non-QSM read pairs for the subsamples for each sample. Pseudorandom read subsampling randomly selects a predefined number of non-QSM read pairs according to a seed. The seed ensures that the entire subsampling is random, which is also reproducible.

[0216] In one embodiment, a known amount of an internal quantification standard added to a sample can be used to calculate the input quantity (IQT) of an unknown nucleic acid(s) in the sample after normalization according to Equation 6. IQT = Normalized number of unknown nucleic acid sequencing reads attributable to unknown nucleic acids * (Input amount of internal quantification standard / F) [Equation 6]

[0217] For example, referring back to sample B in FIG. 9, using Equation 6, the IQT of unknown nucleic acid X can be calculated as follows: after normalization, there were 500 reads attributable to X, and "F" was set at 5000, so IQT=500*(10 / 5000)=1. Many samples have more than one unknown nucleic acid. Thus, the input quantities (IQTi, IQTj, IQTk···IQTn) of multiple unknown nucleic acids in a sample can be calculated by Equation 7 after normalization. IQTn = normalized number of unknown "n" nucleic acid sequencing reads attributable to the "nth" unknown nucleic acid * (input amount of internal quantification standard / F) [Equation 7]

[0218] After counting the normalized number of reads attributable to each distinct unknown nucleic acid (e.g., by alignment, pseudo-alignment, or assembly methods), these normalized read numbers can be used to determine the input concentration of each unknown nucleic acid.

[0219] The same principle applies to pooled samples. Each pooled sample has its own unique set of QSM and sample-specific identification sequences, so that the sequencing data from each sample in the pool can be differentiated and separated. Thus, normalization can be applied separately to the sequencing data from each sample in the pool. Thus, each sample in a sample pool has its own (1) data pass / fail criteria, and (2) substantially the same limit of detection (LOD) is applied to all unknown nucleic acids in each sample. This is important because, as explained in Figures 10 and 11, some samples may be highly concentrated, some may have nucleic acids at or near the LOD, and some samples may over-read or under-read for QSM, while some samples may read at or near the pass criteria for QSM. For example, as explained for samples 6, 9, 10, and 14, the QSM for some samples may be over-proportioned in the pooled data set, while others 15, 17, 26, and 32, etc., have QSM values ​​at or near the pass criteria. Evaluating QSMs separately and applying normalization to each sample is compelling for the following reasons: (1) it ensures that each sample has sufficient read depth (some individual samples can be rejected without having to reject the entire data set), (2) it ensures that highly enriched samples do not swamp out low concentration samples, (3) it ensures that the same LOD is applied to all samples, and (4) it ensures that an objectively significant amount of data is evaluated from each sample for normalization and quantification. Thus, Equation 7 can be used to calculate the input amounts of multiple nucleic acids in multiple samples in a pool.

[0220] In some embodiments, the steps of preparing a sample for sequencing may include specific procedures. In one embodiment, the steps of preparing a sample for sequencing may include sample lysis, nucleic acid recovery from the lysate (the recovered nucleic acid may be purified), and the introduction of a sequencing adaptor site and a sample-specific identification sequence to the region of the nucleic acid to be sequenced. In one embodiment, the sequencing adaptor site may include a region for attaching the nucleic acid to a platform for sequencing (e.g., a flow cell) and a sequencing primer binding site. An example of a sample preparation workflow is illustrated in FIG. 13. In some embodiments, the internal quantification standard / QSM may be added before or after lysis, depending on the possibility that the QSM may be damaged or fragmented by, for example, the lysis protocol. For example, if sample lysis includes bead-beating or sonication, the QSM may be added after lysis but before the recovery and purification of the nucleic acid. If chemical lysis or gentle mechanical lysis is used, the QSM may be added before lysis.

[0221] In an illustrative example, it is believed that the internal quantification standard can be used to estimate the true input concentration of unknown nucleic acid in the original sample by accounting for losses during sample preparation and sequencing.That is, the internal quantification standard is retained throughout all steps of analysis.Therefore, any losses are systematic, and the sequenced concentration can be used to back-calculate the true input concentration by attributing losses to sample extraction, sequencing, etc., and is the same for each sample throughout the entire process.

[0222] In one embodiment, the step of introducing a sequencing adapter site and a sample-specific discrimination sequence may comprise one of the following steps: (1) amplifying the nucleic acid to be sequenced in an amplification reaction using a target-specific primer comprising the sample-specific discrimination sequence and a sequencing primer binding site, or (2) fragmenting the nucleic acid to be sequenced and ligating a sequencing-specific adapter comprising the sequencing primer binding site and the sample-specific discrimination sequence to the fragmented nucleic acid.

[0223] In one embodiment, amplifying the nucleic acid to be sequenced may include: performing a first multiplex PCR reaction with target-specific primers having custom overhangs, performing a first nucleic acid purification, performing a second PCR reaction with a sequencing adapter primer that anneals or ligates to the custom overhangs introduced in the first PCR, and performing a second nucleic acid purification. In one embodiment, the sequencing adapter primer is target-independent and comprises a sequencing primer adapter site and a sample-specific identification sequence.

[0224] As illustrated in Figure 14, the total bioload in a typical sample ranges widely from about 0 to 10 13 organisms / ml (typically about 10 2 ~10 7 ) can vary. This can result in a very wide range of nucleic acid copies / ml being input to the sequencing reaction. In one embodiment, an amplification reaction can be used to reduce the upper range of the reaction so that the sample subjected to sequencing contains a smaller relative dynamic range of nucleic acid numbers (e.g., about 10 2 ~10 7 In one embodiment, the method described herein effectively has a 10 7 To plateau the amplification of nucleic acids present at concentrations greater than copies / ml and to reach a plateau of approximately 10 in the exponential amplification phase. 7The method may include limiting one or more of the cycle number or the concentration of the target-specific primers in the first multiplex PCR reaction to preserve the nucleic acid at less than copies / ml. This is illustrated in Figure 15. For example, the upper LOD of the sequencing assay is about 10 copies / ml of each nucleic acid. 2 ~10 7 It can be linear in the range of copies. 7 Above nucleic acid copies / ml, it is desirable to avoid the need to oversequence such concentrated nucleic acids that are outside the linear range of the assay; such nucleic acids should be >10 7 It may be reported as having an input concentration reported as nucleic acid copies / ml, whereas a concentration of about 10 2 ~10 7 All nucleic acids are kept within the linear range of the assay and reported at their true input amounts by the corresponding number of normalized sequencing reads. In some embodiments, it may be desirable to limit the lower end of the dynamic concentration range by limiting the number of amplification cycles. In one embodiment, the LOD of the assay may specify a lower reporting range, and nucleic acids below the LOD may be reported as "not detected."

[0225] In one embodiment, the input amount of nucleic acid in the sample can instead be reported semi-quantitatively or in a "binned" range. In many embodiments, absolute quantification is not necessary, and semi-quantitative results can be sufficient. Furthermore, reporting binned ranges can be simpler and can allow reporting to account for target-specific errors in the data. Results can be reported as absolute concentrations (with or without systematic errors (e.g., 95% prediction intervals)) or binned into one of several ranges, e.g., reporting "high", "medium" or "low" concentrations, each covering one or more orders of magnitude.

[0226] Similarly, the input amount of nucleic acid in a sample can be reported in numerical bins, an example of which is shown in Table 2 below. JPEG0007590954000002.jpg58166

[0227] Each bin encompasses values ​​spanning 1 log; bins are defined as ranges including 0.5 logs on either side of the bin label (i.e., a 10^5 bin contains amounts from 10^4.5 to 10^5.5, etc.). The extra 0.5 logs on either side of the bin range are to account for measurement variability found near the bin boundaries. The exceptions described in Table 2 are the lowest bin where any value below 10^3.5 can be reported as "not detected" and the highest bin where any value above 10^6.5 can be reported as >10^7. However, these lower and upper reported values ​​are merely illustrative, and it is understood that a range of different lower and upper reported values ​​can be used depending on factors such as, but not limited to, the LOD and dynamic range of a given assay. Two standard deviations, or 0.5 logs from the bin boundary, is the theoretical range that captures 95% of the data points that do not fall on the bin boundary. It is understood that the number of bins may be varied as appropriate for a particular assay, and any number of bins may be used, and the binning range (order of magnitude or other scale) for semi-quantitative results may also be adjusted as appropriate for a particular example.

[0228] Example 5: Method for performing comparator testing When a diagnostic testing provider (e.g., BioFire Diagnostics) develops a new commercial diagnostic test, the test provider is often required by the FDA to perform a comparator study to provide validation that the new commercial test produces the results that the provider claims. Typically, the comparator assay uses a unique and well-accepted gold standard technique, such as a standard of care (SOC) culture method, to check the results of the new assay. However, current SOC culture methods cannot provide highly accurate or consistent detection and quantification of bacterial targets in clinical samples. This is due to a number of factors, including the often enhanced sensitivity of molecular assays versus culture, the fact that culture can only detect live organisms, and the challenge of working up unique colony morphologies from complex, organism-rich specimen types.

[0229] For molecular assays such as the FilmArray system described herein, which uses PCR and fluorescence detection to detect the presence of organisms in samples, Sanger sequencing is an accepted alternative comparator for SOC culture methods.However, as molecular assays become more complex, the sequencing load of traditional Sanger sequencing becomes greater.Similarly, if quantification is claimed by commercial testing, comparator sequencing assays may also need to provide quantitative or semi-quantitative results.

[0230] Described herein is a high-throughput alternative to conventional PCR and bidirectional sequencing comparator methods previously used in the field.Preferably, the sequencing method used in comparator testing is next-generation sequencing (NGS) or similar massively parallel sequencing technology.For targets on diagnostic panels that require semi-quantitative biological load reporting (e.g., bacteria, viruses, fungi, etc.), or antibiotic resistance markers associated with some bacteria, a quantitative or semi-quantitative molecular reference method has been developed as a preferred embodiment for use as a comparator during clinical trials.The novel molecular reference method described herein takes advantage of the inherently digital and massively parallel nature of NGS.Although the specific embodiment discussed herein uses Illumina NGS, the principles described herein can be applied to other sequencing platforms with minimal modification.

[0231] In one embodiment, a method for performing a comparator test is described. The method for performing a comparator test may include providing a first assay comprising multiplex amplification and detection of one or more target nucleic acids, where the first assay has a limit of detection (LOD), and providing a second assay, different from the first assay, for confirming the detection and LOD of the first assay. The second assay may include: preparing a sample including at least one internal quantification standard for sequencing; sequencing to produce a sequencing dataset for the sample, where the sequencing dataset includes sequencing reads observed from the target nucleic acid(s) and the internal quantification standard; counting the number of sequencing reads in the sequencing dataset derived from the target nucleic acid(s) and the internal quantification standard; and normalizing the sequencing dataset, where normalizing includes (1) applying a data pass / fail criterion to the sequencing dataset based on the presence of a minimum number of sequencing reads for the internal quantification standard for the sample, and (2) ensuring that a substantially identical limit of detection (LOD) is applied to all unknown nucleic acids in the sequencing assay. The LOD of the second assay is preferably substantially identical to the LOD of the first assay.

[0232] The results of the second assay may be compared to the results of the first assay. Preferably, the organisms and amounts of organisms detected in the first assay should match the detection and amounts reported by the second assay.

[0233] In one embodiment, the first assay may comprise adding one or more internal quantification standards to the sample and subjecting the sample to a quantitative two-step amplification. In one embodiment, the quantitative two-step amplification in the first assay comprises: amplifying the sample in a first-stage multiplex amplification mixture, where the amplification mixture comprises a plurality of target primers and at least one quantification standard primer, each target primer configured to amplify a different target that may be present in the sample and the quantification standard primer configured to amplify an internal quantification standard nucleic acid; dividing the first-stage amplification mixture into a plurality of second-stage individual reactions, where a first group of the plurality of second-stage individual reactions each comprise at least one primer configured to further amplify one of the different targets that may be present in the sample and a second group of the plurality of second-stage individual reactions each comprise at least one primer configured to further amplify one of the internal quantification standard nucleic acids; and subjecting the plurality of second-stage individual reactions to amplification conditions to produce one or more target amplicons and a plurality of quantification standard amplicons, where each quantification standard amplicon has a related quantification standard Cp. Each target nucleic acid has a crossing point (Cp) and each internal standard has a known concentration in the first assay and a known quantification standard Cp.

[0234] In one embodiment, the input concentration of the unknown nucleic acid in the first assay may be determined by comparison with the known input concentration of the quantification standard. In one embodiment, the method may further comprise the steps of creating a calibration curve from the quantification standard Cp, and quantifying each of the one or more target nucleic acids using the calibration curve. In one embodiment, each of the target nucleic acids is quantified using a calibration curve created using a least squares regression line fitted to Equation 3. Log 10 (Concentration)=(Cp-b) / a [Equation 3]

[0235] In Equation 3, Cp is the crossing point measured for each target, b (the intercept) represents the Cp value when the log10(concentration) of the target is zero, and a is the slope, which represents the degree to which Cp changes with a single unit change in concentration.

[0236] Referring back to the second assay, the data from the second assay can be normalized and the input amount of unknown nucleic acid can be determined as described in Example 4 above. Importantly, a threshold checkpoint of read depth based on a pre-determined expected number of QSM reads precedes target-specific analysis. Samples with insufficient read depth are flagged for further sequencing, while samples with sufficient read depth are normalized. This ensures that the quantitative value of the reads is the same across all samples, and that target detection is independent of overall target load.

[0237] The predetermined expected number of QSM reads (i.e., "F") can be selected to be comparable to the first assay with respect to different detection limits. For example, if the QSM is 5×10 5 copies / ml, and "F" is 5 x 10 3 then the LOD for detection of the target nucleic acid(s) in the second assay is about 10 2 ~10 3 copies / ml. Similarly, "F" is in the range of 5 x 10 4 then the LOD for detection of the target nucleic acid(s) in the second assay is about 10 1 ~10 2 copies / ml. In general, the larger the magnitude of "F", the smaller the LOD for the sequencing assay. This is because the larger the magnitude of "F", the greater the sequencing depth of the assay, as explained in detail in Example 4. The spike level of QSM (e.g., 5×10 5The relationship between semi-quantitative binned target reports in terms of copies / ml), "F" (e.g., "F" = 5000), read counts, and representative normalized read counts at each reporting level is described in Table 3. JPEG0007590954000003.jpg52166

[0238] Similarly, as described above, multiple samples can be pooled for sequencing assay.Pooling is not necessary, but its true power is shown when it comes to massively parallel DNA sequencing.For example, the ability to pool and sequence in parallel greatly reduces the time and manpower required to perform comparator tests.Samples can be pooled, normalized, and quantified as described above in Example 4.

[0239] Example 6: Assay-specific correction factors Ideally, next generation sequencing (NGS) should report exactly the same target quantification as any other quantitative molecular method, such as digital PCR. However, the reality is that variability in sampling and measurement may exist in each reference method, and such randomness often prevents this perfect match scenario from being achieved. One possible solution is to report data with appropriate error ranges or to bin the data. However, if the errors are assay-specific and not uniform / systematic across all sample types, error ranges or binning may not account for all of the errors in the data.

[0240] On the other hand, assay-specific correction factors can be used to further account for repetitive and systematic factors such as differences in nucleic acid amplification efficiency, differences in nucleic acid purification efficiency, differences in sequencing library preparation, and differences in sequencing efficiency.Since such differences are repetitive and systematic for a given sample, analyte, and / or assay, they can be measured and used to provide assay-specific correction factors for correcting target quantification.The NGS method described herein can use assay-specific correction factors to remove the systematic differences in target quantification performance for multiple targets observed across many (e.g., more than 50) experimental measurements.

[0241] The assay-specific correction factor described in this example was obtained by analyzing assay-specific positive control (PC) sequences in more than 50 batch positive controls. PC sequences can be added to the test samples or included as separate samples in each run. Prior to amplification, the batch positive controls can be spiked with a mixture of PC sequences (e.g., modified gBlocks) at known concentrations (e.g., 50 copies of each PC gBlock per reaction), as well as quantification standard materials (e.g., 500 copies of QSM per reaction). If the PCR amplification is not perfectly efficient, or if the efficiencies of the target and internal standard differ, the correction factor can depend on the amount of positive control input into the reaction. Thus, in one embodiment, the amount of positive control should be in the middle of the intended dynamic range of the corresponding target. In one embodiment, the PC sequences can be designed to be amplified with the same target-specific primers with overhangs used in the test assay, so that the sample-specific sequencing adapter primers can anneal to the amplified PC sequences in the same manner as the test assay. Naturally, the positive control is designed to have its own unique identifying sequence region between the conserved primer binding site regions. In this way, the sequencing data derived from the positive control can be identified and analyzed separately. The PC sequence may contain assay-specific targets, ensuring that each assay performs identically (e.g., 10 4.7 copies / mL), would be expected to be quantified at a comparable level.

[0242] However, FIG. 16 shows that two populations of assays were observed. For the purposes of this example, the two populations of assays are referred to as good performers and bad performers. The assays referred to as good performers are seen on the left of the graph (A-M) and the assays referred to as bad performers are seen on the right of the graph (O-X). Sample N is an intermediate performer. The mean log10 quantification of the good performers is consistently close to the expected quantification, whereas the mean log10 quantification of the bad performers is not. That is, one can infer that the "good performers" are consistently quantified in the test assay near their expected performance, whereas the "bad performers" are consistently quantified in the test assay at values ​​significantly worse than their expected performance. More specifically, good performers are defined as assays with mean log10 quantification within 0.5 log10 of expected quantification, whereas bad performers are defined as assays with mean log10 quantification 0.5 log10 or more lower than expected quantification. The mean log10 quantification of good performers is 0.23 log10 lower than expected quantification, whereas the mean log10 quantification of poor performers is 1.0 log10 lower than expected quantification. One assay of intermediate performance was observed (shown in N).

[0243] The assay-specific correction factors described in this example are the mean log10 quantification of the respective assay and the mean log10 quantification of the good performers (10 4.47 The correction factors were defined as the difference between the concentration of IgG1 and IgG2 (copies / mL) and allowed for correction factors up to 1.0 log10. In this example, assay-specific correction factors were obtained for a particular set of assays. However, one of skill in the art will understand that the principles described in this example can be adapted and applied to other assays with only minimal assay-specific modifications.

[0244] Example 7: Kit for normalizing and quantifying unknown nucleic acids in next-generation sequencing (NGS) assays In one embodiment, a kit for normalizing and quantifying unknown nucleic acids in a next generation sequencing (NGS) assay is disclosed. The kit may include an internal quantification standard (wherein the internal quantification standard is a nucleic acid configured to be added in a known amount to a sample containing the unknown nucleic acid to be sequenced) and instructions for using the internal quantification standard to normalize and quantify a sequencing data set and to calculate the input amount of the unknown nucleic acid(s). In one embodiment, the kit may include a set of internal quantification standards that are added at different known concentrations to create a calibration curve for the quantification of the unknown nucleic acid. In one embodiment, the internal quantification standard is about 10 4 ~10 6 The internal quantification standard may be configured to be added to the sample in the range of copies / ml. In one embodiment, using an internal quantification standard, the sequencing data may be normalized according to Equation 5. NORM = number of sequencing reads * (F / number of observed sequencing reads derived from internal quantification standard) [Equation 5] where "F" is the fixed minimum expected number of sequencing reads for the internal quantification standard. In one embodiment, using the internal quantification standard, the input quantity (IQT) of the unknown nucleic acid can be calculated by Equation 6: IQT = Normalized number of unknown nucleic acid sequencing reads attributable to unknown nucleic acids * (Input amount of internal quantification standard / F) [Equation 6]

[0245] In one embodiment, the kit may further comprise a sequencing specific adaptor for at least an internal quantification standard, the adaptor comprising a sequencing primer binding site and a sample specific identification sequence. In one embodiment, the kit may further comprise a target specific primer with a custom overhang configured for amplification of the internal quantification standard and for annealing or ligating to the sequencing specific adaptor.

[0246] The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be understood in all respects as merely illustrative and not limiting. The scope of the present invention is therefore indicated by the appended claims rather than the foregoing description. Although specific embodiments and details have been included in this specification and the accompanying invention disclosure for the purpose of illustrating the present invention, it will be apparent to those skilled in the art that various modifications in the methods and apparatus disclosed herein can be made without departing from the scope of the present invention as defined in the appended claims. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims

1. 1. A method for normalization of read values ​​of a sequencing assay, comprising: Providing a sample containing one or more unknown nucleic acids to be sequenced; adding a known amount of an internal quantification standard to the sample; setting a minimum number of sequencing reads for the internal quantification standard; preparing a sample containing said internal quantification standard for sequencing; wherein said preparing step comprises introducing a sequencing-specific adapter site and a sample-specific identification sequence to said one or more unknown nucleic acids in said sample and said internal quantification standard; sequencing to produce a sequencing dataset for said sample; wherein the sequencing dataset comprises unknown nucleic acid sequencing reads observed from the one or more unknown nucleic acids and internal quantification standard sequencing reads observed from the internal quantification standard; counting the number of sequencing reads in the sequencing dataset derived from the one or more unknown nucleic acids and the internal quantification standard; determining whether a minimum number of sequencing reads for the internal quantification standard has been reached in the sequencing dataset and determining that a sufficient sequencing read depth has been reached in the sequencing dataset to detect at least one of the one or more unknown nucleic acids present in the sample at or above a limit of detection (LOD); In response to determining that a sufficient sequencing read depth for the sample has been reached, normalizing the sequencing dataset to provide a normalized sequencing dataset; and Quantifying at least one of the one or more unknown nucleic acids present in the sample at a concentration greater than the LOD based on the normalized sequencing dataset; or subjecting the sample to additional sequencing if the minimum number of sequencing reads for the internal quantification standard has not been reached in the sequencing data set; Including, method.

2. 2. The method of claim 1, Each unknown nucleic acid in the sample is about 10 2 ~10 7 having a concentration of copies / ml, method.

3. 2. The method of claim 1, The known amount of the internal quantification standard added to the sample is about 10 4 ~10 6 copies / ml range, method.

4. 2. The method of claim 1, Normalizing the sequencing dataset comprises maintaining NORM sequencing reads; where NORM = number of sequencing reads * (F / number of observed sequencing reads derived from the internal quantification standard), where "F" is a fixed minimum expected number of sequencing reads for the internal quantification standard; method.

5. 5. The method of claim 4, wherein the unknown nucleic acid reads and the internal quantification standard reads are each separately normalized by the same ratio ALPHA, where ALPHA=F / the number of observed sequencing reads derived from the internal quantification standard; method.

6. 2. The method of claim 1, calculating at least one input quantity (IQT) of said one or more unknown nucleic acids in said sample after normalization; Wherein, since the input amount of the internal quantification standard is known, the input amount (IQT) of at least one of the one or more unknown nucleic acids can be calculated by IQT = normalized number of unknown nucleic acid sequencing reads attributable to the unknown nucleic acid * (input amount of internal quantification standard / F); method.

7. 2. The method of claim 1, The step of preparing the sample includes the steps of lysing the sample, recovering nucleic acid from the lysate, which may be purified, and introducing a primer binding site and a sample-specific identification sequence within the region of the nucleic acid to be sequenced. method.

8. 8. The method of claim 7, The step of preparing the sample comprises: amplifying the nucleic acid to be sequenced in an amplification reaction using a target-specific primer having a dual-indexed sequencing overhang that includes a sequencing primer binding site and a sample-specific identification sequence; or fragmenting the nucleic acid to be sequenced and ligating a sequencing-specific adapter comprising a sequencing primer binding site and a sample-specific identification sequence to the fragmented nucleic acid. including one of method.

9. 9. The method of claim 8, The step of amplifying the nucleic acid to be sequenced comprises: performing a first multiplex PCR reaction using target-specific primers with custom overhangs; performing a first nucleic acid purification; performing a second PCR reaction using a dual-indexed sequencing adapter primer that anneals or ligates to the overhangs introduced in the first PCR; wherein the dual-index sequencing adapter primer is target-independent and comprises a sequencing primer binding site and a sample-specific identification sequence; performing a second nucleic acid purification; Including, method.

10. 2. The method of claim 1, further comprising pooling two or more samples and subjecting them to sequencing simultaneously; wherein the two or more samples are pooled after preparation and prior to sequencing; method.

11. 2. The method of claim 1, The sequencing assay is a next-generation sequencing assay. method.

12. 2. The method of claim 1, The sequencing assay comprises: Relative quantification, quantification in a reaction separate from the sequencing assay, using assay or template specific quantification standards, or using competing templates as quantification standards. Does not include method.

13. 2. The method of claim 1, Quantifying at least one of the one or more unknown nucleic acids present in the sample at a concentration greater than an LOD based on the normalized sequencing dataset comprises quantifying the concentration using a known amount of an internal quantification standard added to the sample, a number of sequencing reads counted for the internal quantification standard, and a number of sequencing reads counted for the at least one of the one or more unknown nucleic acids. method.

14. 2. The method of claim 1, The LOD for the sequencing assay is based on a known amount of an internal quantification standard added to the sample and the minimum number of sets of sequencing reads required for the internal quantification standard. method.

15. 2. The method of claim 1, Normalizing the sequencing dataset includes applying a data pass / fail criterion to the sequencing dataset based on a minimum number of sequencing reads relative to an internal quantification standard for the sample, and applying substantially the same limit of detection (LOD) to all unknown nucleic acids in the sequencing assay. method.

16. 16. The method of claim 15, The normalized sequencing data is scaled by the ratio of the minimum number of sequencing reads for the internal quantification standard to the number of sequencing reads counted for the internal quantification standard. method.

Citation Information

Patent Citations

  • Quantification of nucleic acid molecules using multiplex PCR

    US20090136951A1

  • Systems and methods to detect rare mutations and copy number variation

    WO2014039556A1